<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Epidemiol Infect</journal-id><journal-id journal-id-type="iso-abbrev">Epidemiol Infect</journal-id><journal-id journal-id-type="pmc-domain-id">326</journal-id><journal-id journal-id-type="pmc-domain">epidinfect</journal-id><journal-id journal-id-type="publisher-id">HYG</journal-id><journal-title-group><journal-title>Epidemiology and Infection</journal-title></journal-title-group><issn pub-type="ppub">0950-2688</issn><issn pub-type="epub">1469-4409</issn><publisher><publisher-name>Cambridge University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8220514</article-id><article-id pub-id-type="pmcid-ver">PMC8220514.1</article-id><article-id pub-id-type="pmcaid">8220514</article-id><article-id pub-id-type="pmcaiid">8220514</article-id><article-id pub-id-type="pmid">34032200</article-id><article-id pub-id-type="doi">10.1017/S0950268821001229</article-id><article-id pub-id-type="pii">S0950268821001229</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Design of a new multi-epitope vaccine against <italic toggle="yes">Brucella</italic> based on T and B cell epitopes using bioinformatics methods</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Z">Zhiqiang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="fns1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="Y">Yuejie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="author-notes" rid="fns1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sha</surname><given-names initials="T">Tong</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Z">Zhiwei</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yujiao</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="F">Fengbo</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5506-7665</contrib-id><name name-style="western"><surname>Ding</surname><given-names initials="J">Jianbing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Immunology, College of Basic Medicine, <institution>Xinjiang Medical University</institution>, <city>Urumqi</city>, <postal-code>830011</postal-code>
<state>Xinjiang</state>, <country>China</country></aff><aff id="aff2"><label>2</label>Department of Reproductive Assistance, Center for Reproductive Medicine, <institution>The First Affiliated Hospital of Xinjiang Medical University</institution>, No. 393, Xinyi Road, <city>Urumqi</city>, <postal-code>830011</postal-code>
<state>Xinjiang</state>, <country>China</country></aff><aff id="aff3"><label>3</label>Clinical Laboratory Center, <institution>Xinjiang Uygur Autonomous Region People's Hospital</institution>, <city>Urumqi</city>, <postal-code>830001</postal-code>
<state>Xinjiang</state>, <country>China</country></aff><aff id="aff4"><label>4</label>Department of Clinical Laboratory, <institution>The First Affiliated Hospital of Xinjiang Medical University</institution>, No. 393, Xinyi Road, <city>Urumqi</city>, <postal-code>830011</postal-code>
<state>Xinjiang</state>, <country>China</country></aff><aff id="aff5"><label>5</label>State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases, <institution>the First Affiliated Hospital of Xinjiang Medical University</institution>, No. 393, Xinyi Road, <city>Urumqi</city>, <postal-code>830011</postal-code>
<state>Xinjiang</state>, <country>China</country></aff><author-notes><corresp id="cor1"><bold>Author for correspondence:</bold> Jianbing Ding, E-mail: <email>1601379937@qq.com</email>; Fengbo Zhang, E-mail: <email>765219598@qq.com</email></corresp><fn id="fns1" fn-type="other"><label>*</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2021"><year>2021</year></pub-date><pub-date pub-type="epub"><day>25</day><month>5</month><year>2021</year></pub-date><volume>149</volume><issue-id pub-id-type="pmc-issue-id">380051</issue-id><elocation-id>e136</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2020</year></date><date date-type="rev-recd"><day>14</day><month>5</month><year>2021</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>05</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>01</day><month>07</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-04 17:25:14.210"><day>04</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="S0950268821001229a.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="S0950268821001229a.pdf"/><abstract abstract-type="normal"><p>Brucellosis is one of the most serious and widespread zoonotic diseases, which seriously threatens human health and the national economy. This study was based on the T/B dominant epitopes of <italic toggle="yes">Brucella</italic> outer membrane protein 22 (Omp22), outer membrane protein 19 (Omp19) and outer membrane protein 28 (Omp28), with bioinformatics methods to design a safe and effective multi-epitope vaccine. The amino acid sequences of the proteins were found in the National Center for Biotechnology Information (NCBI) database, and the signal peptides were predicted by the SignaIP-5.0 server. The surface accessibility and hydrophilic regions of proteins were analysed with the ProtScale software and the tertiary structure model of the proteins predicted by I-TASSER software and labelled with the UCSF Chimera software. The software COBEpro, SVMTriP and BepiPred were used to predict B cell epitopes of the proteins. SYFPEITHI, RANKpep and IEDB were employed to predict T cell epitopes of the proteins. The T/B dominant epitopes of three proteins were combined with HEYGAALEREAG and GGGS linkers, and carriers sequences linked to the N- and C-terminus of the vaccine construct with the help of EAAAK linkers. Finally, the tertiary structure and physical and chemical properties of the multi-epitope vaccine construct were analysed. The allergenicity, antigenicity and solubility of the multi-epitope vaccine construct were 7.37&#8211;11.30, 0.788 and 0.866, respectively. The Ramachandran diagram of the mock vaccine construct showed 96.0% residues within the favoured and allowed range. Collectively, our results showed that this multi-epitope vaccine construct has a high-quality structure and suitable characteristics, which may provide a theoretical basis for future laboratory experiments.</p></abstract><kwd-group><title>Key words</title><kwd><italic toggle="yes">Brucella</italic></kwd><kwd>multi-epitope vaccine</kwd><kwd>Omp22</kwd><kwd>Omp19</kwd><kwd>Omp28</kwd></kwd-group><kwd-group kwd-group-type="abbreviations"><title>Abbreviations</title><kwd>Omp22, outer membrane protein</kwd><kwd>Omp19, outer membrane protein 19</kwd><kwd>Omp28, outer membrane protein</kwd><kwd>NCBI, National Center for Biotechnology Information</kwd><kwd>DNA, desoxyribonucleic acid</kwd><kwd>LPS, lipopolysaccharide</kwd><kwd>Cu/Zn SOD, Cu-Zn superoxide dismutase</kwd><kwd>TCR, T cell receptor</kwd><kwd>BCR, B cell receptor</kwd><kwd>C-score, confident score</kwd><kwd>HBHA, heparin-binding haemagglutinin</kwd><kwd>TM, template modelling</kwd><kwd>RMSD, root mean square deviation</kwd><kwd>MHC, major histocompatibility complex</kwd><kwd>GRAVY, grand average of hydropathicity</kwd><kwd>3D, three-dimensional</kwd><kwd>HLA, human leucocyte antigen</kwd><kwd>CTLs, cytotoxic T lymphocytes</kwd><kwd>ACC, auto cross covariance</kwd><kwd><italic toggle="yes">E. coli</italic>, <italic toggle="yes">Escherichia coli</italic></kwd></kwd-group><counts><fig-count count="7"/><table-count count="28"/><ref-count count="41"/><page-count count="18"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p><italic toggle="yes">Brucella</italic> is a Gram-negative intracellular pathogen that causes brucellosis [<xref rid="ref1" ref-type="bibr">1</xref>], it usually can be divided into 12 species in nature, including six so-called classic <italic toggle="yes">Brucella</italic> species, namely <italic toggle="yes">B. melitensis, B. abortus, B. suis, B. canis, B. ovis</italic> and <italic toggle="yes">B. neotomae</italic>, and six newly discovered <italic toggle="yes">Brucella</italic> species from wild mammals, amphibians and fish, namely <italic toggle="yes">B. microti, B. pinnipidialis, B. ceti, B. inopinata, B. papionis</italic> and <italic toggle="yes">B. vulpis.</italic> In the genus <italic toggle="yes">Brucella, B. melitensis, B. abortus</italic> and <italic toggle="yes">B. suis</italic> have good clinical significance [<xref rid="ref2" ref-type="bibr">2</xref>&#8211;<xref rid="ref4" ref-type="bibr">4</xref>]. Brucellosis in animals manifests itself in miscarriages and reduced fertility and is transmitted to humans by inhaling aerosolised bacteria or ingesting contaminated derivatives. Clinical symptoms of human brucellosis include undulant fever, arthritis and general weakness [<xref rid="ref5" ref-type="bibr">5</xref>, <xref rid="ref6" ref-type="bibr">6</xref>]. At the present medical level, it is difficult to completely eliminate <italic toggle="yes">Brucella</italic> [<xref rid="ref7" ref-type="bibr">7</xref>]. Therefore, the vaccine is an ideal way to prevent <italic toggle="yes">Brucella</italic> infection [<xref rid="ref8" ref-type="bibr">8</xref>]. Currently, there are no <italic toggle="yes">Brucella</italic> vaccines for humans, and the live-attenuated vaccines designed for animals have many defects, including interference with serological testing and human infectivity [<xref rid="ref9" ref-type="bibr">9</xref>]. Therefore, the subunit vaccine with no hidden danger and good protective effect has become a new hotspot in brucellosis research. The research of <italic toggle="yes">Brucella</italic> subunit vaccine mainly includes desoxyribonucleic acid (DNA) vaccines, lipopolysaccharide (LPS) vaccines and protein vaccines [<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref11" ref-type="bibr">11</xref>]. With the rapid development of bioinformatics technology, epitopes of different antigens can be constructed as a novel vaccine with good immune effects.</p><p>In previous studies, a series of different proteins from <italic toggle="yes">Brucella</italic> has been used to identify immunodominant antigens against <italic toggle="yes">Brucella</italic> infection, including outer membrane proteins [<xref rid="ref12" ref-type="bibr">12</xref>], flagellar proteins [<xref rid="ref13" ref-type="bibr">13</xref>&#8211;<xref rid="ref15" ref-type="bibr">15</xref>], L7/L12 ribosomal proteins [<xref rid="ref16" ref-type="bibr">16</xref>] and Cu&#8722;Zn superoxide dismutase (Cu/Zn SOD) [<xref rid="ref17" ref-type="bibr">17</xref>], etc. The Omp22 protein is an immunodominant antigen, belonging to the Omp25/Omp31 family of proteins. It is highly conserved among various species of <italic toggle="yes">Brucella</italic> and is related to the infectivity of <italic toggle="yes">Brucella</italic>. Studies have shown that the Omp22 protein is similar to the LPS of <italic toggle="yes">Brucella</italic> and induces an immune response in the body [<xref rid="ref18" ref-type="bibr">18</xref>]. The Omp19 is exposed at the cell surface of <italic toggle="yes">Brucella</italic> spp, and it can be employed for protection against <italic toggle="yes">Brucella</italic> [<xref rid="ref19" ref-type="bibr">19</xref>]. The Omp28 is also an important outer membrane protein of <italic toggle="yes">Brucella</italic>. It is highly conserved among various genera. It has been reported that the Omp28 peptide with CpG oligonucleotide as an adjuvant can induce an immune response mediated by IgG2a type, indicating that the Omp28 can induce the body to produce large amounts of IgG antibodies [<xref rid="ref20" ref-type="bibr">20</xref>]. It has been known that vaccines constructed from a single protein stimulate poor immune responses and that multiple protein combinations enhance the vaccine's immune response [<xref rid="ref21" ref-type="bibr">21</xref>]. Therefore, in this study, based on the T/B epitopes of Omp22, Omp19 and Omp28, a multi-epitope vaccine against <italic toggle="yes">Brucella</italic> was constructed. To verify the availability of the vaccine construct, the tertiary structure, secondary structure, physical and chemical properties, solubility, antigenicity and allergenicity of the vaccine construct were analysed by various bioinformatics software. The results indicated that the multi-epitope vaccine construct could be used as a candidate protein against <italic toggle="yes">Brucella.</italic></p></sec><sec sec-type="methods" id="sec2"><title>Methods</title><sec id="sec2-1" sec-type="other"><title>Amino acid sequence of the protein</title><p>The amino acid sequences of the Omp22, Omp19, Omp28 were searched in the GenBank database (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/genbank/">https://www.ncbi.nlm.nih.gov/genbank/</uri>).</p></sec><sec id="sec2-2" sec-type="other"><title>Prediction of signal peptide</title><p>SignalP-5.0 Server [<xref rid="ref22" ref-type="bibr">22</xref>] was used to predict the signal peptide of the protein sequence. SP (Sec/SPI) is related to the type of signal peptide predicted; CS represents the cleavage site; Other: the probability that the sequence does not have any kind of signal peptide.</p></sec><sec id="sec2-3" sec-type="other"><title>Identification of hydrophilic residues and surface accessible</title><p>Immunoglobulins usually bind to the water-accessible regions of antigens. Thus, the predicted epitopes should ideally be located in the highly hydrophilic region with many accessible residues. Surface accessible and hydrophilic regions of the protein were determined using the ProtScale software [<xref rid="ref23" ref-type="bibr">23</xref>] and marked these areas through UCSF Chimera software [<xref rid="ref24" ref-type="bibr">24</xref>].</p></sec><sec id="sec2-4" sec-type="other"><title>Prediction of tertiary structure</title><p>The I-TASSER server [<xref rid="ref25" ref-type="bibr">25</xref>] automatically generated high-quality tertiary structure models of protein molecules from amino acid sequences. The structure and function of proteins were predicted by I-TASSER based on analytic hierarchy process. Here, we used the confidence score (C score) to evaluate the predictive model quality. The C score is in the range of &#8211; 5 to 2, where the higher C score, the higher credibility of the model. The template modelling (TM) score was used to deal with some error-sensitive root mean-square deviation (RMSD) problems. A TM score &lt;0.17 indicates random similarity, and only a TM score&gt;0.5 could indicate a correct topology model. These cutoff values did not depend on the length of the protein.</p></sec><sec id="sec2-5" sec-type="other"><title>B cell epitope prediction</title><p>To ensure the accuracy of the prediction of B cell epitopes, we used various prediction software, including COBEpro (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://scratch.proteomics.ics.uci.edu/">http://scratch.proteomics.ics.uci.edu/</uri>), SVMTriP (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://sysbio.unl.edu/SVMTriP/prediction.php">http://sysbio.unl.edu/SVMTriP/prediction.php</uri>) and BepiPred (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.cbs.dtu.dk/services/BepiPred-1.0/">http://www.cbs.dtu.dk/services/BepiPred-1.0/</uri>). The overlapping sequences of the top 10 from at least two software were chosen as B cell dominant epitopes.</p></sec><sec id="sec2-6" sec-type="other"><title>T cell epitope prediction</title><p>T cells can be divided into CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells, which are restricted by the major histocompatibility complex (MHC) in identifying epitopes. Human MHC is called the human leucocyte antigen (HLA) gene complex. CD4<sup>+</sup> T cells recognise antigenic epitopes consisting of 9&#8211;22 amino acid residues, which are limited by their HLA-II molecules and differentiate into T helper cells after activation. CD8<sup>+</sup> T cells recognise epitopes consisting of 8&#8211;12 amino acid residues, which are limited by HLA-I molecules, and differentiate into cytotoxic T lymphocytes (CTLs) after activation. Therefore, it was necessary to predict CD4<sup>+</sup> and CD8<sup>+</sup> T cell epitopes, respectively, when predicting T cell epitopes. We selected HLA-A * 0201 and HLA-A * 2402 discerned by HLA-I and HLA-DRB * 0701 and HLA-DRB * 0901 discerned by HLA-II, which were the four most common alleles in North China. Some different online software was used to predict T cell epitopes, including IEDB (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.iedb.org/home_v3.php">http://www.iedb.org/home_v3.php</uri>), SYFPEITHI (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.syfpeithi.de/bin/mhcserver.dll/epitopeprediction">http://www.syfpeithi.de/bin/mhcserver.dll/epitopeprediction</uri>) and RANKPEP (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://imed.med.ucm.es/Tools/rankpep.html">http://imed.med.ucm.es/Tools/rankpep.html</uri>). We listed the top 10 high-score epitopes for each prediction software and selected three software overlapping sequences as T cell dominant epitopes for the proteins.</p></sec><sec id="sec2-7" sec-type="other"><title>Predicting immunogenicity and antigenicity of CD8<sup>+</sup> T cell epitopes</title><p>Epitope/HLA complexes should be capable of eliciting strong immune responses. Therefore, we used the HLA I immunogenicity prediction tool of the IEDB server, the parameters were set to default. The antigenic properties of all CD8<sup>+</sup> T cell epitopes were analysed using VaxiJen 2.0 Server [<xref rid="ref26" ref-type="bibr">26</xref>] with a threshold of 0.5. Finally, we selected CD8<sup>+</sup> T cell epitopes with immunogenicity and antigenicity for the next step (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://tools.immuneepitope.org/immunogenicity/">http://tools.immuneepitope.org/immunogenicity/</uri>).</p></sec><sec id="sec2-8" sec-type="other"><title>Multi-epitope vaccine sequence construction</title><p>The predicted T/B dominant antigen epitopes were linked by some amino acid linkers. To enhance the immunogenicity of the epitope vaccine, heparin-binding haemagglutinin (HBHA) conservative sequences were added to epitope sequences as the carrier [<xref rid="ref27" ref-type="bibr">27</xref>]. It is also known that the PADRE peptides can induce CD4<sup>+</sup> T cells and enhance the immune function of the vaccine construct [<xref rid="ref28" ref-type="bibr">28</xref>].</p></sec><sec id="sec2-9" sec-type="other"><title>Assessment of allergenicity, antigenicity and solubility</title><p>The allergenicity of the vaccine construct was predicted by SDAP [<xref rid="ref29" ref-type="bibr">29</xref>]. SDAP can predict the cross-reactivity of candidate vaccines and known allergens through the allergenicity rules of WHO. We chose the default parameter, which was a similarity of more than 35% for full-length sequences, and an E cutoff of 0.01 when the sliding window was aligned to 80 amino acids, and 6 adjacent short amino acid sequences matched with known allergens. The antigenicity of the vaccine construct by VaxiJen 2.0 server. This server relies on auto cross covariance (ACC) transformation, and alignment-independent predicted antigenic epitopes by physiochemical properties of proteins. The SOLpro [<xref rid="ref30" ref-type="bibr">30</xref>] was used to predict the solubility of the vaccine construct. Based on the multiple representation of the first-order amino acid sequence&#65292;two-stage SVM architecture was adopted. The final result is to summarise the prediction with 74% overall accuracy at the corresponding probability (&#179;0.5).</p></sec><sec id="sec2-10" sec-type="other"><title>The secondary structure prediction</title><p>The proportions and distributions of <italic toggle="yes">Alpha helix</italic>, <italic toggle="yes">Beta turn, Random coil, Extended strand</italic> in vaccine construct sequence were predicted and analysed using SOPMA online analysis software [<xref rid="ref31" ref-type="bibr">31</xref>].</p></sec><sec id="sec2-11" sec-type="other"><title>Prediction of various physicochemical properties</title><p>The online tool ProtPararm from Expasy (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.expasy.org/protparam/">http://www.expasy.org/protparam/</uri>) was used to analyse the physicochemical properties of the vaccine, including theoretical isoelectric points, molecular weight, hydrophilicity, atomic composition and extinction coefficient. The physical and chemical properties from the pk values of amino acids were calculated by ProtPararm software.</p></sec><sec id="sec2-12" sec-type="other"><title>Construction of the tertiary structure of the vaccine construct</title><p>The I-TASSER online software was used to construct the vaccine's tertiary structure, which was validated by Ramachandran diagrams in the RAMPAGE webserver. (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://mordred.bioc.cam.ac.uk/~rapper/rampage.php">http://mordred.bioc.cam.ac.uk/~rapper/rampage.php</uri>). The Ramachandran plot is a method to show the allowed and disallowed dihedral angles <italic toggle="yes">psi (&#968;)</italic> and <italic toggle="yes">phi (&#981;)</italic> of amino acid. It is calculated according to van der Waal radius of the side chain.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3-1" sec-type="other"><title>Amino acid sequence of protein</title><p>Obtaining the Omp22 protein sequence from GenBank (Accession: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="AAS84601.1">AAS84601.1</ext-link>): MFKRSITAAALGAAVMAFAGSAFAADMMGGTDYTYNDPVAAGPHDWSGNYVGAQVGGSSSKFPSPFASRTGALGGIVVGKNMQNGNIVFGAELEGNFAEAEHRIGHGGTLQQSWNGNAKGKVGYTFDKTLVYGTAGYGVTRFKAKDNTTSASGWEGGVLIGAGVEQALSGPLSVKAEYDFQRFNDVKSQVNGIEQRNNLKNHSIKAGLNYKF Obtaining the Omp19 protein sequence from GenBank (Accession: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="ERU25360.1">ERU25360.1</ext-link>): MGISKASLLSLAAAGIVLAGCQSSRLGNLDNVSPPPPPAPVNAVPAGTVQKGNLDSPTQFPNAPSTDMSAQSGTQVASLPPASAPDLTPGAVAGVWNASLGGQSCKIATPQTKYGQGYRAGPLRCPGELANLASWAVNGKQLVLYDANGGTVASLYSSGQGRFDGQTTGGQAVTLSR Obtaining the Omp28 protein sequence from GenBank (Accession: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="AEF59021.1">AEF59021.1</ext-link>): MNTRASNFLAASFSTIMLVGAFSLPAFAQENQMTTQPARIAVTGEGMMTASPDMAILNLSVLRQAKTAREAMTANNEAMTKVLDAMKKAGIEDRDLQTGGINIQPIYVYPDDKNNLKEPTITGYSVSTSLTVRVRELANVGKILDESVTLGVNQGGDLNLVNDNPSAVINEARKRAVANAIAKAKTLADAAGVGLGRVVEISELSRPPMPMPIARGQFRTMLAAAPDNSVPIAAGENSYNVSVNVVFEIK</p></sec><sec id="sec3-2" sec-type="other"><title>Signal peptide of proteins</title><p>The signal peptides of Omp22, Omp19 and Omp28 were predicted separately by the SignalP-5.0. Signal peptide sequence of the Omp19 was MGISKASLLSLAAAGIVLA (<xref ref-type="fig" rid="fig01">Fig. 1a</xref>); signal peptide sequence of the Omp22 was MFKRSITAAALGAAVMAFAGSAFA (<xref ref-type="fig" rid="fig01">Fig. 1b</xref>); signal peptide sequence of the Omp28 was MNTRASNFLAASFSTIMLVGAFSLPAFA (<xref ref-type="fig" rid="fig01">Fig. 1c</xref>). All of the three signal peptide sequences were removed from the epitope prediction of Omp22, Omp19 and Omp28.
<fig id="fig01" fig-type="fig" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Signal peptide of proteins using SignalP-5.0 analysis. SP (Sec/SPI): type of signal peptide predicted; CS: the cleavage site; Other: the probability that the sequence does not have any kind of signal peptide. (a) The signal peptide prediction of Omp19: MGISKASLLSLAAAGIVLA. (b) The signal peptide prediction of Omp22: MFKRSITAAALGAAVMAFAGSAFA. (c) The signal peptide prediction of Omp28: MNTRASNFLAASFSTIMLVGAFSLPAFA.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_fig1.jpg"/></fig></p></sec><sec id="sec3-3" sec-type="other"><title>Accessible and hydrophilic region of the proteins</title><p>The accessibility and hydrophilic regions of the Omp22 protein residues and their locations in three-dimensional structures are shown in &#215;<xref ref-type="fig" rid="fig02">Figure 2a</xref> and c. Amino acids 61&#8211;62 and 75&#8211;82 are considered highly unreachable residues due to a surface accessibility score below 5.0 (<xref ref-type="fig" rid="fig02">Fig. 2b</xref>). Amino acids 49&#8211;54 and 132&#8211;140 were estimated to be highly hydrophobic fragments (<xref ref-type="fig" rid="fig02">Fig. 2d</xref>). In the prediction of T/B epitopes, the residual regions of hydrophobicity and inaccessibility are neglected and they are unlikely to bind to specific antibodies.
<fig id="fig02" fig-type="fig" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Solvent accessible and hydrophilic regions of Omp22. (a) The blue residues show the surface-accessible regions of Omp22 as tertiary structure. (b) The accessible residues are displayed as a ProtScale plot. The residues exceeding the threshold (6.0) will be considered surface accessible residues. (c) The green residues displayed the hydrophilic regions of Omp22 as tertiary structure. (d) two highly hydrophobic area (aa45&#8211;54) and (aa132&#8211;140) is marked in brown on the ProtScale hydrophobic plot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_fig2.jpg"/></fig></p><p>The accessibility and hydrophobic residues of the Omp19 protein and their positions in the 3D structure are shown in <xref ref-type="fig" rid="fig03">Figure 3a</xref> and c. Amino acids 102&#8211;107 were considered highly inaccessible areas (<xref ref-type="fig" rid="fig03">Fig. 3b</xref>). The residues between amino acids 70&#8211;78 were predicted to be highly hydrophobic fragments (<xref ref-type="fig" rid="fig03">Fig. 3d</xref>).
<fig id="fig03" fig-type="fig" orientation="portrait" position="float"><label>Fig. 3.</label><caption><p>Solvent accessible and hydrophilic regions of Omp19. (a) The blue residues show the surface-accessible regions of Omp19 as tertiary structure. (b) The accessible residues are displayed as a ProtScale plot. The residues exceeding the threshold (6.0) will be considered surface accessible residues. (c) The green residues displayed the hydrophilic regions of Omp19 as tertiary structure. (d) A highly hydrophobic area (aa70&#8211;78) is marked in brown on the ProtScale hydrophobic plot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_fig3.jpg"/></fig></p><p>The accessibility and hydrophobic residues of the Omp28 protein and their positions in the 3D structure are shown in &#215;<xref ref-type="fig" rid="fig04">Figure 4a</xref> and c. Amino acids 75&#8211;79 and amino acids 179&#8211;194 were considered highly inaccessible areas (<xref ref-type="fig" rid="fig04">Fig. 4b</xref>). The residues between amino acids 27&#8211;33 were predicted to be highly hydrophobic fragments (<xref ref-type="fig" rid="fig04">Fig. 4d</xref>).
<fig id="fig04" fig-type="fig" orientation="portrait" position="float"><label>Fig. 4.</label><caption><p>Solvent accessible and hydrophilic regions of Omp28. (a) The blue residues indicate the surface-accessible regions of Omp28 as tertiary structure. (b) The accessible residues are shown as a ProtScale plot. The residues exceeding the threshold (6.0) will be considered surface accessible residues. (c) The green residues displayed the hydrophilic regions of Omp28 as tertiary structure. (d) A highly hydrophobic area (aa27&#8211;33) is marked in brown on the ProtScale hydrophobic plot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_fig4.jpg"/></fig></p></sec><sec id="sec3-4" sec-type="other"><title>Tertiary structure of proteins</title><p>The I-TASSER online program was employed to model the 3D structure of proteins (<xref ref-type="fig" rid="fig05">Fig. 5</xref>). The C score of the Omp22 prediction model was shown as &#8722;0.56, and the TM score and the RMSD of the model are shown as 0.64&#160;&#177;&#160;0.13 and 6.4&#160;&#177;&#160;3.9&#160;&#197;, respectively, so it had high reliability (<xref ref-type="fig" rid="fig05">Fig. 5a</xref>). The prediction model of the Omp19 was not highly reliable (<xref ref-type="fig" rid="fig05">Fig. 5b</xref>), and its C score was shown as &#8722;3.12. The TM and RMSD were 0.36&#160;&#177;&#160;0.12 and 12.0&#160;&#177;&#160;4.4&#160;&#197;, respectively. The prediction model of the Omp28 was very reliable, with a C score of 0.94. The TM and RMSD are shown as 0.84&#160;&#177;&#160;0.08 and 3.7&#160;&#177;&#160;2.5&#160;&#197;, respectively (<xref ref-type="fig" rid="fig05">Fig. 5c</xref>).
<fig id="fig05" fig-type="fig" orientation="portrait" position="float"><label>Fig. 5.</label><caption><p>Tertiary structure of protein. Multi-coloured ribbon and coil structure represents the helix, sheets and coiled secondary structure component of the 3D model obtained for the protein. (a) Omp22. (b) Omp19. (c) Omp28.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_fig5.jpg"/></fig></p></sec><sec id="sec3-5" sec-type="other"><title>Prediction of B-cell epitopes</title><p>We used online software COBEpro, SVMTriP and BepiPred to screen the predicted Epitopes of B cells and displayed them in tabular form. The B cell epitopes for Omp22, Omp19 and Omp28 are shown in <xref rid="tab01 tab02 tab03" ref-type="table">Tables 1&#8211;3</xref>, respectively.
<table-wrap id="tab01" orientation="portrait" position="float"><label>Table 1.</label><caption><p>B cell epitopes of Omp22</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab1.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">COBEpro</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">158&#8211;163</td><td colspan="1" rowspan="1">FNDVKS</td><td colspan="1" rowspan="1">0.826</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">159&#8211;164</td><td colspan="1" rowspan="1">NDVKSQ</td><td colspan="1" rowspan="1">0.810</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">174&#8211;179</td><td colspan="1" rowspan="1">NLKNHS</td><td colspan="1" rowspan="1">0.748</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">125&#8211;131</td><td colspan="1" rowspan="1">TSASGWE</td><td colspan="1" rowspan="1">0.742</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">40&#8211;46</td><td colspan="1" rowspan="1">SPFASRT</td><td colspan="1" rowspan="1">0.730</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">118&#8211;123</td><td colspan="1" rowspan="1">FKAKDN</td><td colspan="1" rowspan="1">0.579</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">116&#8211;122</td><td colspan="1" rowspan="1">TRFKAKD</td><td colspan="1" rowspan="1">0.700</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">161&#8211;166</td><td colspan="1" rowspan="1">DVKSQV</td><td colspan="1" rowspan="1">0.723</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">169&#8211;175</td><td colspan="1" rowspan="1">IEQRNNL</td><td colspan="1" rowspan="1">0.684</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">123&#8211;129</td><td colspan="1" rowspan="1">NTTSASG</td><td colspan="1" rowspan="1">0.699</td></tr><tr><td colspan="1" rowspan="1">SVMtri</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">119&#8211;138</td><td colspan="1" rowspan="1">KAKDNTTSASGWEGGVLIGA</td><td colspan="1" rowspan="1">1.000</td></tr><tr><td rowspan="4" valign="top" colspan="1">BepiPred</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">4&#8211;45</td><td colspan="1" rowspan="1">MGGTDYTYNDPVAAGPHDW<break/>SGNYVGAQVGGSSSKFPSPFASR</td><td colspan="1" rowspan="1">1.711&#8211;0.571</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">85&#8211;99</td><td colspan="1" rowspan="1">TLQQSWNGNAKGKVG</td><td colspan="1" rowspan="1">1.250&#8211;0.424</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">120&#8211;131</td><td colspan="1" rowspan="1">AKDNTTSASGWE</td><td colspan="1" rowspan="1">1.724&#8211;0.547</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">164&#8211;174</td><td colspan="1" rowspan="1">SQVNGIEQRNN</td><td colspan="1" rowspan="1">0.659&#8211;0.399</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab02" orientation="portrait" position="float"><label>Table 2.</label><caption><p>B cell epitopes of Omp19</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab2.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">COBEpro</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">24&#8211;29</td><td colspan="1" rowspan="1">VPAGTV</td><td colspan="1" rowspan="1">0.814</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">51&#8211;57</td><td colspan="1" rowspan="1">QSGTQVA</td><td colspan="1" rowspan="1">0.744</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">91&#8211;98</td><td colspan="1" rowspan="1">QTKYGQGY</td><td colspan="1" rowspan="1">0.640</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">57&#8211;62</td><td colspan="1" rowspan="1">ASLPPA</td><td colspan="1" rowspan="1">0.721</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">34&#8211;40</td><td colspan="1" rowspan="1">LDSPTQF</td><td colspan="1" rowspan="1">0.718</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">29&#8211;34</td><td colspan="1" rowspan="1">VQKGNL</td><td colspan="1" rowspan="1">0.764</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">40&#8211;47</td><td colspan="1" rowspan="1">FPNAPSTD</td><td colspan="1" rowspan="1">0.699</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">12&#8211;19</td><td colspan="1" rowspan="1">VSPPPPPA</td><td colspan="1" rowspan="1">0.695</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">142&#8211;148</td><td colspan="1" rowspan="1">RFDGQTT</td><td colspan="1" rowspan="1">0.680</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">125&#8211;131</td><td colspan="1" rowspan="1">YDANGGT</td><td colspan="1" rowspan="1">0.638</td></tr><tr><td colspan="1" rowspan="1">SVMtri</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">111&#8211;130</td><td colspan="1" rowspan="1">ANLASWAVNGKQLVLYDANG</td><td colspan="1" rowspan="1">1.000</td></tr><tr><td rowspan="4" valign="top" colspan="1">BepiPred</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">12&#8211;53</td><td colspan="1" rowspan="1">VSPPPPPAPVNAVPAGTVQKGNL<break/>DSPTQFPNAPSTDMSAQSG</td><td colspan="1" rowspan="1">0.539&#8211;2.953</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">57&#8211;75</td><td colspan="1" rowspan="1">ASLPPASAPDLTPGAVAGV</td><td colspan="1" rowspan="1">0.540&#8211;1.654</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">91&#8211;106</td><td colspan="1" rowspan="1">QTKYGQGYRAGPLRCP</td><td colspan="1" rowspan="1">0.564&#8211;0.923</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">144&#8211;153</td><td colspan="1" rowspan="1">DGQTTGGQAV</td><td colspan="1" rowspan="1">0.502&#8211;0.889</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab03" orientation="portrait" position="float"><label>Table 3.</label><caption><p>B cell epitopes of Omp28</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab3.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">COBEpro</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">64&#8211;70</td><td colspan="1" rowspan="1">EDRDLQT</td><td colspan="1" rowspan="1">0.845</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">65&#8211;71</td><td colspan="1" rowspan="1">DRDLQT</td><td colspan="1" rowspan="1">0.839</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">88&#8211;94</td><td colspan="1" rowspan="1">LKEPTI</td><td colspan="1" rowspan="1">0.831</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">86&#8211;92</td><td colspan="1" rowspan="1">NNLKEPT</td><td colspan="1" rowspan="1">0.811</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">133&#8211;138</td><td colspan="1" rowspan="1">VNDNPS</td><td colspan="1" rowspan="1">0.810</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">7&#8211;13</td><td colspan="1" rowspan="1">TQPARIA</td><td colspan="1" rowspan="1">0.754</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">203&#8211;209</td><td colspan="1" rowspan="1">PIAAGEN</td><td colspan="1" rowspan="1">0.731</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">206&#8211;212</td><td colspan="1" rowspan="1">AGENSYN</td><td colspan="1" rowspan="1">0.650</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">3&#8211;13</td><td colspan="1" rowspan="1">NQMTTQPARIA</td><td colspan="1" rowspan="1">0.605</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">8&#8211;14</td><td colspan="1" rowspan="1">QPARIAV</td><td colspan="1" rowspan="1">0.723</td></tr><tr><td rowspan="2" valign="top" colspan="1">SVMtri</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">41&#8211;60</td><td colspan="1" rowspan="1">REAMTANNEAMTKVLDAMKK</td><td colspan="1" rowspan="1">1.000</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">203&#8211;222</td><td colspan="1" rowspan="1">PIAAGENSYNVSVNVVFEIK</td><td colspan="1" rowspan="1">0.845</td></tr><tr><td rowspan="7" valign="top" colspan="1">BepiPred</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">1&#8211;12</td><td colspan="1" rowspan="1">QENQMTTQPARI</td><td colspan="1" rowspan="1">1.258&#8211;0.523</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">39&#8211;49</td><td colspan="1" rowspan="1">AREAMTANNE</td><td colspan="1" rowspan="1">0.830&#8211;0.502</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">62&#8211;73</td><td colspan="1" rowspan="1">GIEDRDLQTGGI</td><td colspan="1" rowspan="1">1.083&#8211;0.330</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">80&#8211;97</td><td colspan="1" rowspan="1">VYPDDKNNLKEPTITGYS</td><td colspan="1" rowspan="1">1.512&#8211;0.565</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">133&#8211;141</td><td colspan="1" rowspan="1">VNDNPSAVI</td><td colspan="1" rowspan="1">0.990&#8211;0.502</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">176&#8211;185</td><td colspan="1" rowspan="1">LSRPPMPMPI</td><td colspan="1" rowspan="1">1.160&#8211;0.629</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">197&#8211;212</td><td colspan="1" rowspan="1">APDNSVPIAAGENSYN</td><td colspan="1" rowspan="1">1.131&#8211;0.518</td></tr></tbody></table></alternatives></table-wrap></p></sec><sec id="sec3-6" sec-type="other"><title>Prediction of T cell epitopes</title><sec id="sec3-6-1" sec-type="other"><title>CD8<sup>+</sup> T cell epitopes</title><p>Online software SYFPEITHI, IEDB and RANKpep were employed to analyse the CD8<sup>+</sup> T cell epitope of the proteins. The analysis results of the Omp22 are shown in <xref rid="tab04 tab05 tab06" ref-type="table">Tables 4&#8211;6</xref>. The analysis results of the Omp19 are shown in <xref rid="tab07 tab08 tab09" ref-type="table">Tables 7&#8211;9</xref>. The analysis results of the Omp28 are shown in <xref rid="tab10 tab11 tab12" ref-type="table">Tables 10&#8211;12</xref>.
<table-wrap id="tab04" orientation="portrait" position="float"><label>Table 4.</label><caption><p>The CD8<sup>+</sup> T cell epitopes of Omp22 by SYFPEITHI</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab4.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">48&#8211;56</td><td colspan="1" rowspan="1">ALGGIVVGK</td><td colspan="1" rowspan="1">21</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">142&#8211;150</td><td colspan="1" rowspan="1">QALSGPLSV</td><td colspan="1" rowspan="1">21</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">135&#8211;143</td><td colspan="1" rowspan="1">LIGAGVEQA</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">126&#8211;134</td><td colspan="1" rowspan="1">SASGWEGGV</td><td colspan="1" rowspan="1">19</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">134&#8211;142</td><td colspan="1" rowspan="1">VLIGAGVEQ</td><td colspan="1" rowspan="1">19</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">143&#8211;151</td><td colspan="1" rowspan="1">ALSGPLSVK</td><td colspan="1" rowspan="1">19</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">2&#8211;10</td><td colspan="1" rowspan="1">DMMGGTDYT</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">61&#8211;69</td><td colspan="1" rowspan="1">GNIVFGAEL</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">47&#8211;55</td><td colspan="1" rowspan="1">GALGGIVVG</td><td colspan="1" rowspan="1">17</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">128&#8211;136</td><td colspan="1" rowspan="1">SGWEGGVLI</td><td colspan="1" rowspan="1">17</td></tr><tr><td rowspan="10" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">72&#8211;80</td><td colspan="1" rowspan="1">NFAEAEHRI</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">41&#8211;49</td><td colspan="1" rowspan="1">PFASRTGAL</td><td colspan="1" rowspan="1">17</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">128&#8211;136</td><td colspan="1" rowspan="1">SGWEGGVLI</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">167&#8211;175</td><td colspan="1" rowspan="1">NGIEQRNNL</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">10&#8211;18</td><td colspan="1" rowspan="1">TYNDPVAAG</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">78&#8211;86</td><td colspan="1" rowspan="1">HRIGHGGTL</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">112&#8211;120</td><td colspan="1" rowspan="1">GYGVTRFKA</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">30&#8211;38</td><td colspan="1" rowspan="1">QVGGSSSKF</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">34&#8211;42</td><td colspan="1" rowspan="1">SSSKFPSPF</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">61&#8211;69</td><td colspan="1" rowspan="1">GNIVFGAEL</td><td colspan="1" rowspan="1">12</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab05" orientation="portrait" position="float"><label>Table 5.</label><caption><p>The CD8<sup>+</sup> T cell epitopes of Omp22 by IEDB</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab5.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Percentile rank</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">9&#8211;17</td><td colspan="1" rowspan="1">YTYNDPVAA</td><td colspan="1" rowspan="1">0.34</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">128&#8211;136</td><td colspan="1" rowspan="1">SGWEGGVLI</td><td colspan="1" rowspan="1">1.9</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">142&#8211;150</td><td colspan="1" rowspan="1">QALSGPLSV</td><td colspan="1" rowspan="1">2.4</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">100&#8211;108</td><td colspan="1" rowspan="1">YTFDKTLVY</td><td colspan="1" rowspan="1">2.8</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">57&#8211;65</td><td colspan="1" rowspan="1">NMQNGNIVF</td><td colspan="1" rowspan="1">2.8</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">135&#8211;143</td><td colspan="1" rowspan="1">LIGAGVEQA</td><td colspan="1" rowspan="1">3.0</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">3&#8211;11</td><td colspan="1" rowspan="1">MMGGTDYTY</td><td colspan="1" rowspan="1">3.6</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">68&#8211;76</td><td colspan="1" rowspan="1">ELEGNFAEA</td><td colspan="1" rowspan="1">4.1</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">72&#8211;80</td><td colspan="1" rowspan="1">NFAEAEHRI</td><td colspan="1" rowspan="1">4.6</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">2&#8211;10</td><td colspan="1" rowspan="1">DMMGGTDYT</td><td colspan="1" rowspan="1">4.6</td></tr><tr><td rowspan="10" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">107&#8211;115</td><td colspan="1" rowspan="1">VYGTAGYGV</td><td colspan="1" rowspan="1">0.13</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">57&#8211;65</td><td colspan="1" rowspan="1">NMQNGNIVF</td><td colspan="1" rowspan="1">0.51</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">72&#8211;80</td><td colspan="1" rowspan="1">NFAEAEHRI</td><td colspan="1" rowspan="1">0.57</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">99&#8211;107</td><td colspan="1" rowspan="1">GYTFDKTLV</td><td colspan="1" rowspan="1">1.1</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">158&#8211;166</td><td colspan="1" rowspan="1">RFNDVKSQV</td><td colspan="1" rowspan="1">1.3</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">110&#8211;118</td><td colspan="1" rowspan="1">TAGYGVTRF</td><td colspan="1" rowspan="1">1.8</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">151&#8211;159</td><td colspan="1" rowspan="1">KAEYDFQRF</td><td colspan="1" rowspan="1">1.9</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">180&#8211;188</td><td colspan="1" rowspan="1">IKAGLNYKF</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">3&#8211;11</td><td colspan="1" rowspan="1">MMGGTDYTY</td><td colspan="1" rowspan="1">2.1</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">94&#8211;102</td><td colspan="1" rowspan="1">AKGKVGYTF</td><td colspan="1" rowspan="1">2.2</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab06" orientation="portrait" position="float"><label>Table 6.</label><caption><p>The CD8<sup>+</sup> T cell epitopes of Omp22 by RANKPEP</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab6.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="4" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">158&#8211;168</td><td colspan="1" rowspan="1">RFNDVKSQV</td><td colspan="1" rowspan="1">55.0</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">135&#8211;143</td><td colspan="1" rowspan="1">LIGAGVEQA</td><td colspan="1" rowspan="1">54.0</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">174&#8211;182</td><td colspan="1" rowspan="1">NIKNHSIKA</td><td colspan="1" rowspan="1">53.0</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">142&#8211;150</td><td colspan="1" rowspan="1">QALSGPLSV</td><td colspan="1" rowspan="1">53.0</td></tr><tr><td rowspan="4" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">72&#8211;80</td><td colspan="1" rowspan="1">NFAEAEHRI</td><td colspan="1" rowspan="1">12.3</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">41&#8211;49</td><td colspan="1" rowspan="1">PFASRTGAL</td><td colspan="1" rowspan="1">12.2</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">107&#8211;115</td><td colspan="1" rowspan="1">VYGTAGYGV</td><td colspan="1" rowspan="1">9.6</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">14&#8211;22</td><td colspan="1" rowspan="1">PVAAGPHDW</td><td colspan="1" rowspan="1">3.9</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab07" orientation="portrait" position="float"><label>Table 7.</label><caption><p>The CD8<sup>+</sup> T cell epitopes of Omp19 by SYFPEITHI</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab7.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">68&#8211;76</td><td colspan="1" rowspan="1">TPGAVAGVL</td><td colspan="1" rowspan="1">25</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">80&#8211;88</td><td colspan="1" rowspan="1">SLGGQSCKI</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">128&#8211;136</td><td colspan="1" rowspan="1">ANGGTVASL</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">117&#8211;125</td><td colspan="1" rowspan="1">AVNGKQLVL</td><td colspan="1" rowspan="1">21</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">5&#8211;13</td><td colspan="1" rowspan="1">SRLGNLDNV</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">148&#8211;156</td><td colspan="1" rowspan="1">TTGGQAVTL</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">73&#8211;81</td><td colspan="1" rowspan="1">VAGVWNASL</td><td colspan="1" rowspan="1">19</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">52&#8211;60</td><td colspan="1" rowspan="1">QSGTQVASL</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">105&#8211;113</td><td colspan="1" rowspan="1">RCPGELANL</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">110&#8211;118</td><td colspan="1" rowspan="1">LANLASWAV</td><td colspan="1" rowspan="1">18</td></tr><tr><td rowspan="10" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">136&#8211;144</td><td colspan="1" rowspan="1">LYSSGQGRF</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">33&#8211;41</td><td colspan="1" rowspan="1">GNLDSPTQF</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">102&#8211;110</td><td colspan="1" rowspan="1">GPLRCPGEL</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">60&#8211;68</td><td colspan="1" rowspan="1">LPPASAPDL</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">73&#8211;81</td><td colspan="1" rowspan="1">VAGVWNASL</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">80&#8211;88</td><td colspan="1" rowspan="1">SLGGQSCKI</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">105&#8211;113</td><td colspan="1" rowspan="1">RCPGELANL</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">2&#8211;10</td><td colspan="1" rowspan="1">CQSSRLGNL</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">52&#8211;60</td><td colspan="1" rowspan="1">QSGTQVASL</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">94&#8211;102</td><td colspan="1" rowspan="1">KYGQGYRAG</td><td colspan="1" rowspan="1">11</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab08" orientation="portrait" position="float"><label>Table 8.</label><caption><p>The CD8<sup>+</sup> T cell epitopes of Omp19 by IEDB</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab8.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Percentile rank</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">124&#8211;132</td><td colspan="1" rowspan="1">VLYDANGGT</td><td colspan="1" rowspan="1">1.3</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">71&#8211;79</td><td colspan="1" rowspan="1">GAVAGVWNA</td><td colspan="1" rowspan="1">1.7</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">68&#8211;76</td><td colspan="1" rowspan="1">LTPGAVAGV</td><td colspan="1" rowspan="1">1.7</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">80&#8211;88</td><td colspan="1" rowspan="1">SLGGQSCKI</td><td colspan="1" rowspan="1">2.1</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">55&#8211;63</td><td colspan="1" rowspan="1">TQVASLPPA</td><td colspan="1" rowspan="1">2.7</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">117&#8211;126</td><td colspan="1" rowspan="1">AVNGKQLVL</td><td colspan="1" rowspan="1">2.9</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">146&#8211;154</td><td colspan="1" rowspan="1">GQTTGGQAV</td><td colspan="1" rowspan="1">3.9</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">39&#8211;47</td><td colspan="1" rowspan="1">TQFPNAPST</td><td colspan="1" rowspan="1">4.0</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">12&#8211;20</td><td colspan="1" rowspan="1">NVSPPPPPA</td><td colspan="1" rowspan="1">4.0</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">64&#8211;72</td><td colspan="1" rowspan="1">SAPDLTPGA</td><td colspan="1" rowspan="1">4.1</td></tr><tr><td rowspan="10" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">136&#8211;144</td><td colspan="1" rowspan="1">LYSSGQGRF</td><td colspan="1" rowspan="1">0.1</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">115&#8211;123</td><td colspan="1" rowspan="1">SWAVNGKQL</td><td colspan="1" rowspan="1">0.59</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">125&#8211;133</td><td colspan="1" rowspan="1">LYDANGGTV</td><td colspan="1" rowspan="1">0.79</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">33&#8211;41</td><td colspan="1" rowspan="1">GNLDSPTQF</td><td colspan="1" rowspan="1">2.9</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">108&#8211;116</td><td colspan="1" rowspan="1">GELANLASW</td><td colspan="1" rowspan="1">4.0</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">117&#8211;125</td><td colspan="1" rowspan="1">AVNGKQLVL</td><td colspan="1" rowspan="1">5.2</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">148&#8211;156</td><td colspan="1" rowspan="1">TTGGQAVTL</td><td colspan="1" rowspan="1">5.7</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">5&#8211;13</td><td colspan="1" rowspan="1">SRLGNLDNV</td><td colspan="1" rowspan="1">5.7</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">68&#8211;76</td><td colspan="1" rowspan="1">LTPGAVAGV</td><td colspan="1" rowspan="1">6.8</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">94&#8211;102</td><td colspan="1" rowspan="1">KYGQGYRAG</td><td colspan="1" rowspan="1">6.9</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab09" orientation="portrait" position="float"><label>Table 9.</label><caption><p>The CD8<sup>+</sup> T cell epitopes of Omp19 by RANKPEP</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab9.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="3" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">80&#8211;88</td><td colspan="1" rowspan="1">SLGGQSCKI</td><td colspan="1" rowspan="1">76.0</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">117&#8211;125</td><td colspan="1" rowspan="1">AVNGKQLVL</td><td colspan="1" rowspan="1">63.0</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">68&#8211;76</td><td colspan="1" rowspan="1">LTPGAVAGV</td><td colspan="1" rowspan="1">50.0</td></tr><tr><td rowspan="3" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">136&#8211;144</td><td colspan="1" rowspan="1">LYSSGQGRF</td><td colspan="1" rowspan="1">16.3</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">115&#8211;123</td><td colspan="1" rowspan="1">SWAVNGKQL</td><td colspan="1" rowspan="1">16.0</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">125&#8211;133</td><td colspan="1" rowspan="1">LYDANGGTV</td><td colspan="1" rowspan="1">8.0</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab10" orientation="portrait" position="float"><label>Table 10.</label><caption><p>The CD8<sup>+</sup> T cell epitopes of Omp28 by SYFPEITHI</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab10.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">101&#8211;109</td><td colspan="1" rowspan="1">SLTVRVREL</td><td colspan="1" rowspan="1">27</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">114&#8211;122</td><td colspan="1" rowspan="1">KILDESVTL</td><td colspan="1" rowspan="1">26</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">25&#8211;33</td><td colspan="1" rowspan="1">DMAILNLSV</td><td colspan="1" rowspan="1">23</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">162&#8211;170</td><td colspan="1" rowspan="1">AAGVGLGRV</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">194&#8211;202</td><td colspan="1" rowspan="1">LAAAPDNSV</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">165&#8211;173</td><td colspan="1" rowspan="1">VGLGRVVEI</td><td colspan="1" rowspan="1">21</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">26&#8211;34</td><td colspan="1" rowspan="1">MAILNLSVL</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">72&#8211;80</td><td colspan="1" rowspan="1">GINIQPIYV</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">148&#8211;156</td><td colspan="1" rowspan="1">AVANAIAKA</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">157&#8211;165</td><td colspan="1" rowspan="1">KTLADAAGV</td><td colspan="1" rowspan="1">20</td></tr><tr><td rowspan="9" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">80&#8211;88</td><td colspan="1" rowspan="1">VYPDDKNNL</td><td colspan="1" rowspan="1">25</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">165&#8211;173</td><td colspan="1" rowspan="1">VGLGRVVEI</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">107&#8211;115</td><td colspan="1" rowspan="1">RELANVGKI</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">213&#8211;221</td><td colspan="1" rowspan="1">VSVNVVFEI</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">114&#8211;122</td><td colspan="1" rowspan="1">KILDESVTL</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">177&#8211;185</td><td colspan="1" rowspan="1">SRPPMPMPI</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">151&#8211;159</td><td colspan="1" rowspan="1">NAIAKAKTL</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">196&#8211;205</td><td colspan="1" rowspan="1">AAPDNSVPI</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">21&#8211;29</td><td colspan="1" rowspan="1">TASPDMAIL</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">26&#8211;34</td><td colspan="1" rowspan="1">MAILNLSVL</td><td colspan="1" rowspan="1">12</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab11" orientation="portrait" position="float"><label>Table 11.</label><caption><p>The CD8<sup>+</sup> T cell epitopes of Omp28 by IEDB</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab11.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Percentile rank</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">114&#8211;122</td><td colspan="1" rowspan="1">KILDESVTL</td><td colspan="1" rowspan="1">0.07</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">72&#8211;80</td><td colspan="1" rowspan="1">GINIQPIYV</td><td colspan="1" rowspan="1">0.36</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">18&#8211;26</td><td colspan="1" rowspan="1">GMMTASPDM</td><td colspan="1" rowspan="1">0.71</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">132&#8211;140</td><td colspan="1" rowspan="1">LVNDNPSAV</td><td colspan="1" rowspan="1">0.75</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">157&#8211;165</td><td colspan="1" rowspan="1">KTLADAAGV</td><td colspan="1" rowspan="1">0.84</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">131&#8211;139</td><td colspan="1" rowspan="1">NLVNDNPSA</td><td colspan="1" rowspan="1">0.84</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">148&#8211;156</td><td colspan="1" rowspan="1">AVANAIAKA</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">50&#8211;58</td><td colspan="1" rowspan="1">AMTKVLDAM</td><td colspan="1" rowspan="1">1.5</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">209&#8211;217</td><td colspan="1" rowspan="1">NSYNVSVNV</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">205&#8211;213</td><td colspan="1" rowspan="1">AAGENSYNV</td><td colspan="1" rowspan="1">2.1</td></tr><tr><td rowspan="10" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">80&#8211;88</td><td colspan="1" rowspan="1">VYPDDKNNL</td><td colspan="1" rowspan="1">0.13</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">210&#8211;218</td><td colspan="1" rowspan="1">SYNVSVNVV</td><td colspan="1" rowspan="1">0.31</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">182&#8211;190</td><td colspan="1" rowspan="1">PMPIARGQF</td><td colspan="1" rowspan="1">0.84</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">211&#8211;219</td><td colspan="1" rowspan="1">YNVSVNVVF</td><td colspan="1" rowspan="1">1.6</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">177&#8211;185</td><td colspan="1" rowspan="1">SRPPMPMPI</td><td colspan="1" rowspan="1">2.5</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">114&#8211;122</td><td colspan="1" rowspan="1">KILDESVTL</td><td colspan="1" rowspan="1">2.7</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">213&#8211;221</td><td colspan="1" rowspan="1">VSVNVVFEI</td><td colspan="1" rowspan="1">3.1</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">165&#8211;173</td><td colspan="1" rowspan="1">VGLGRVVEI</td><td colspan="1" rowspan="1">3.2</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">73&#8211;81</td><td colspan="1" rowspan="1">INIQPIYVY</td><td colspan="1" rowspan="1">4.1</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">196&#8211;204</td><td colspan="1" rowspan="1">AAPDNSVPI</td><td colspan="1" rowspan="1">4.4</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab12" orientation="portrait" position="float"><label>Table 12.</label><caption><p>The CD8<sup>+</sup> T cell epitopes of Omp28 by RANKPEP</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab12.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="5" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">114&#8211;122</td><td colspan="1" rowspan="1">KILDESVTL</td><td colspan="1" rowspan="1">82.0</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">101&#8211;109</td><td colspan="1" rowspan="1">SLTVRVREL</td><td colspan="1" rowspan="1">77.0</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">148&#8211;156</td><td colspan="1" rowspan="1">AVANAIAKA</td><td colspan="1" rowspan="1">73.0</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">4&#8211;12</td><td colspan="1" rowspan="1">QMTTQPARI</td><td colspan="1" rowspan="1">71.0</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">50&#8211;58</td><td colspan="1" rowspan="1">AMTKVLDAM</td><td colspan="1" rowspan="1">69.0</td></tr><tr><td rowspan="5" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">80&#8211;88</td><td colspan="1" rowspan="1">VYPDDKNNL</td><td colspan="1" rowspan="1">8.7</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">101&#8211;109</td><td colspan="1" rowspan="1">SLTVRVREL</td><td colspan="1" rowspan="1">6.7</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">210&#8211;218</td><td colspan="1" rowspan="1">SYNVSVNVV</td><td colspan="1" rowspan="1">6.0</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">108&#8211;116</td><td colspan="1" rowspan="1">ELANVGKIL</td><td colspan="1" rowspan="1">5.6</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">4&#8211;12</td><td colspan="1" rowspan="1">QMTTQPARI</td><td colspan="1" rowspan="1">5.3</td></tr></tbody></table></alternatives></table-wrap></p></sec><sec id="sec3-6-2" sec-type="other"><title>CD4<sup>+</sup> T cell epitopes</title><p>Online software SYFPEITHI, IEDB and RANKpep were employed to analyse the CD4<sup>+</sup> T cell epitope of the proteins. The analysis results of the Omp22 are shown in <xref rid="tab13 tab14 tab15" ref-type="table">Tables 13&#8211;15</xref>. The analysis results of the Omp19 are shown in <xref rid="tab16 tab17 tab18" ref-type="table">Tables 16&#8211;18</xref>. The analysis results of the Omp28 are shown in <xref rid="tab19 tab20 tab21" ref-type="table">Tables 19&#8211;21</xref>.
<table-wrap id="tab13" orientation="portrait" position="float"><label>Table 13.</label><caption><p>The CD4<sup>+</sup> T cell epitopes of Omp22 by SYFPEITHI</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab13.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">95&#8211;109</td><td colspan="1" rowspan="1">KGKVGYTFDKTLVYG</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">137&#8211;151</td><td colspan="1" rowspan="1">GAGVEQALSGPLSVK</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">83&#8211;97</td><td colspan="1" rowspan="1">GGTLQQSWNGNAKGK</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">97&#8211;111</td><td colspan="1" rowspan="1">KVGYTFDKTLVYGTA</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">104&#8211;118</td><td colspan="1" rowspan="1">KTLVYGTAGYGVTRF</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">4&#8211;18</td><td colspan="1" rowspan="1">MGGTDYTYNDPVAAG</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">28&#8211;42</td><td colspan="1" rowspan="1">GAQVGGSSSKFPSPF</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">38&#8211;52</td><td colspan="1" rowspan="1">FPSPFASRTGALGGI</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">62&#8211;76</td><td colspan="1" rowspan="1">NIVFGAELEGNFAEA</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">133&#8211;147</td><td colspan="1" rowspan="1">GVLIGAGVEQALSGP</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab14" orientation="portrait" position="float"><label>Table 14.</label><caption><p>The CD4<sup>+</sup> T cell epitopes of Omp22 by IEDB</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab14.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Percentile rank</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">136&#8211;150</td><td colspan="1" rowspan="1">IGAGVEQALSGPLSV</td><td colspan="1" rowspan="1">12.00</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">137&#8211;151</td><td colspan="1" rowspan="1">GAGVEQALSGPLSVK</td><td colspan="1" rowspan="1">13.00</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">138&#8211;152</td><td colspan="1" rowspan="1">AGVEQALSGPLSVKA</td><td colspan="1" rowspan="1">14.00</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">103&#8211;117</td><td colspan="1" rowspan="1">DKTLVYGTAGYGVTR</td><td colspan="1" rowspan="1">15.00</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">102&#8211;116</td><td colspan="1" rowspan="1">FDKTLVYGTAGYGVT</td><td colspan="1" rowspan="1">15.00</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">104&#8211;118</td><td colspan="1" rowspan="1">KTLVYGTAGYGVTRF</td><td colspan="1" rowspan="1">15.00</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">101&#8211;115</td><td colspan="1" rowspan="1">TFDKTLVYGTAGYGV</td><td colspan="1" rowspan="1">15.00</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">105&#8211;119</td><td colspan="1" rowspan="1">TLVYGTAGYGVTRFK</td><td colspan="1" rowspan="1">15.00</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">155&#8211;169</td><td colspan="1" rowspan="1">DFQRFNDVKSQVNGI</td><td colspan="1" rowspan="1">16.00</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">96&#8211;110</td><td colspan="1" rowspan="1">GKVGYTFDKTLVYGT</td><td colspan="1" rowspan="1">16.00</td></tr><tr><td rowspan="10" valign="top" colspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">138&#8211;152</td><td colspan="1" rowspan="1">AGVEQALSGPLSVKA</td><td colspan="1" rowspan="1">5.40</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">137&#8211;151</td><td colspan="1" rowspan="1">GAGVEQALSGPLSVK</td><td colspan="1" rowspan="1">5.70</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">136&#8211;150</td><td colspan="1" rowspan="1">IGAGVEQALSGPLSV</td><td colspan="1" rowspan="1">6.00</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">135&#8211;149</td><td colspan="1" rowspan="1">LIGAGVEQALSGPLS</td><td colspan="1" rowspan="1">12.00</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">84&#8211;98</td><td colspan="1" rowspan="1">GTLQQSWNGNAKGKV</td><td colspan="1" rowspan="1">13.00</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">139&#8211;153</td><td colspan="1" rowspan="1">GVEQALSGPLSVKAE</td><td colspan="1" rowspan="1">13.00</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">134&#8211;148</td><td colspan="1" rowspan="1">VLIGAGVEQALSGPL</td><td colspan="1" rowspan="1">13.00</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">140&#8211;154</td><td colspan="1" rowspan="1">VEQALSGPLSVKAEY</td><td colspan="1" rowspan="1">15.00</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">174&#8211;188</td><td colspan="1" rowspan="1">NLKNHSIKAGLNYKF</td><td colspan="1" rowspan="1">17.00</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">86&#8211;100</td><td colspan="1" rowspan="1">LQQSWNGNAKGKVGY</td><td colspan="1" rowspan="1">20.00</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab15" orientation="portrait" position="float"><label>Table 15.</label><caption><p>The CD4<sup>+</sup> T cell epitopes of Omp22 by RANKPEP</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab15.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="4" valign="top" colspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">159&#8211;167</td><td colspan="1" rowspan="1">FNDVKSQVN</td><td colspan="1" rowspan="1">11.1</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">154&#8211;162</td><td colspan="1" rowspan="1">YDFQRFNDV</td><td colspan="1" rowspan="1">11.0</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">53&#8211;61</td><td colspan="1" rowspan="1">VVGKNMQNG</td><td colspan="1" rowspan="1">9.2</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">43&#8211;51</td><td colspan="1" rowspan="1">ASRTGALGG</td><td colspan="1" rowspan="1">8.9</td></tr><tr><td rowspan="4" valign="top" colspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">26&#8211;34</td><td colspan="1" rowspan="1">YVGAQVGGS</td><td colspan="1" rowspan="1">16.4</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">100&#8211;108</td><td colspan="1" rowspan="1">YTFDKTLVY</td><td colspan="1" rowspan="1">15.9</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">90&#8211;98</td><td colspan="1" rowspan="1">WNGNAKGKV</td><td colspan="1" rowspan="1">14.8</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">22&#8211;30</td><td colspan="1" rowspan="1">WSGNYVGAQ</td><td colspan="1" rowspan="1">14.4</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab16" orientation="portrait" position="float"><label>Table 16.</label><caption><p>The CD4<sup>+</sup> T cell epitopes of Omp19 by SYFPEITHI</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab16.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">38&#8211;52</td><td colspan="1" rowspan="1">PTQFPNAPSTDMSAQ</td><td colspan="1" rowspan="1">32</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">107&#8211;121</td><td colspan="1" rowspan="1">PGELANLASWAVNGK</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">57&#8211;71</td><td colspan="1" rowspan="1">VASLPPASAPDLTPG</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">70&#8211;84</td><td colspan="1" rowspan="1">PGAVAGVWNASLGGQ</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">122&#8211;136</td><td colspan="1" rowspan="1">QLVLYDANGGTVASL</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">133&#8211;147</td><td colspan="1" rowspan="1">VASLYSSGQGRFDGQ</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">47&#8211;61</td><td colspan="1" rowspan="1">TDMSAQSGTQVASLP</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">113&#8211;127</td><td colspan="1" rowspan="1">LASWAVNGKQLVLYD</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">141&#8211;155</td><td colspan="1" rowspan="1">QGRFDGQTTGGQAVT</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">19&#8211;33</td><td colspan="1" rowspan="1">PAPVNAVPAGTVQKG</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1"/></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab17" orientation="portrait" position="float"><label>Table 17.</label><caption><p>The CD4<sup>+</sup> T cell epitopes of Omp19 by IEDB</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab17.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Percentile rank</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">106&#8211;120</td><td colspan="1" rowspan="1">CPGELANLASWAVNG</td><td colspan="1" rowspan="1">7.20</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">108&#8211;122</td><td colspan="1" rowspan="1">GELANLASWAVNGKQ</td><td colspan="1" rowspan="1">7.20</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">104&#8211;118</td><td colspan="1" rowspan="1">LRCPGELANLASWAV</td><td colspan="1" rowspan="1">7.20</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">107&#8211;121</td><td colspan="1" rowspan="1">PGELANLASWAVNGK</td><td colspan="1" rowspan="1">7.20</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">105&#8211;119</td><td colspan="1" rowspan="1">RCPGELANLASWAVN</td><td colspan="1" rowspan="1">7.20</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">109&#8211;123</td><td colspan="1" rowspan="1">ELANLASWAVNGKQL</td><td colspan="1" rowspan="1">16.00</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">110&#8211;124</td><td colspan="1" rowspan="1">LANLASWAVNGKQLV</td><td colspan="1" rowspan="1">16.00</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">111&#8211;125</td><td colspan="1" rowspan="1">ANLASWAVNGKQLVL</td><td colspan="1" rowspan="1">27.00</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">113&#8211;127</td><td colspan="1" rowspan="1">LASWAVNGKQLVLYD</td><td colspan="1" rowspan="1">27.00</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">112&#8211;126</td><td colspan="1" rowspan="1">NLASWAVNGKQLVLY</td><td colspan="1" rowspan="1">27.00</td></tr><tr><td rowspan="10" valign="top" colspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">54&#8211;68</td><td colspan="1" rowspan="1">GTQVASLPPASAPDL</td><td colspan="1" rowspan="1">4.10</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">51&#8211;65</td><td colspan="1" rowspan="1">AQSGTQVASLPPASA</td><td colspan="1" rowspan="1">4.50</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">52&#8211;66</td><td colspan="1" rowspan="1">QSGTQVASLPPASAP</td><td colspan="1" rowspan="1">4.70</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">53&#8211;67</td><td colspan="1" rowspan="1">SGTQVASLPPASAPD</td><td colspan="1" rowspan="1">4.70</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">55&#8211;69</td><td colspan="1" rowspan="1">TQVASLPPASAPDLT</td><td colspan="1" rowspan="1">4.80</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">62&#8211;76</td><td colspan="1" rowspan="1">PASAPDLTPGAVAGV</td><td colspan="1" rowspan="1">6.80</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">63&#8211;77</td><td colspan="1" rowspan="1">ASAPDLTPGAVAGVW</td><td colspan="1" rowspan="1">6.90</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">65&#8211;79</td><td colspan="1" rowspan="1">APDLTPGAVAGVWNA</td><td colspan="1" rowspan="1">7.10</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">64&#8211;78</td><td colspan="1" rowspan="1">SAPDLTPGAVAGVWN</td><td colspan="1" rowspan="1">7.10</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">66&#8211;80</td><td colspan="1" rowspan="1">PDLTPGAVAGVWNAS</td><td colspan="1" rowspan="1">7.20</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab18" orientation="portrait" position="float"><label>Table 18.</label><caption><p>The CD4<sup>+</sup> T cell epitopes of Omp19 by RANKPEP</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab18.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="3" valign="top" colspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">98&#8211;106</td><td colspan="1" rowspan="1">GYRAGPLRC</td><td colspan="1" rowspan="1">18.3</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">75&#8211;83</td><td colspan="1" rowspan="1">GVWNASLGG</td><td colspan="1" rowspan="1">11.4</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">24&#8211;32</td><td colspan="1" rowspan="1">AVPAGTVQK</td><td colspan="1" rowspan="1">10.9</td></tr><tr><td rowspan="3" valign="top" colspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">116&#8211;124</td><td colspan="1" rowspan="1">WAVNGKQLV</td><td colspan="1" rowspan="1">10.6</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">77&#8211;85</td><td colspan="1" rowspan="1">WNASLGGQS</td><td colspan="1" rowspan="1">8.5</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">96&#8211;104</td><td colspan="1" rowspan="1">GQGYRAGPL</td><td colspan="1" rowspan="1">5.5</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab19" orientation="portrait" position="float"><label>Table 19.</label><caption><p>The CD4<sup>+</sup> T cell epitopes of Omp28 by SYFPEITHI</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab19.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">93&#8211;107</td><td colspan="1" rowspan="1">ITGYSVSTSLTVRVR</td><td colspan="1" rowspan="1">32</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">9&#8211;23</td><td colspan="1" rowspan="1">PARIAVTGEGMMTA</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">95&#8211;109</td><td colspan="1" rowspan="1">GYSVSTSLTVRVREL</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">113&#8211;127</td><td colspan="1" rowspan="1">GKILDESVTLGVNQG</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">17&#8211;31</td><td colspan="1" rowspan="1">EGMMTASPDMAILNL</td><td colspan="1" rowspan="1">28</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">109&#8211;113</td><td colspan="1" rowspan="1">LANVGKILDESVTLG</td><td colspan="1" rowspan="1">28</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">191&#8211;205</td><td colspan="1" rowspan="1">RTMLAAAPDNSVPIA</td><td colspan="1" rowspan="1">28</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">208&#8211;212</td><td colspan="1" rowspan="1">ENSYNVSVNVVFEIK</td><td colspan="1" rowspan="1">28</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">15&#8211;39</td><td colspan="1" rowspan="1">TGEGMMTASPDMAIL</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">130&#8211;144</td><td colspan="1" rowspan="1">LNLVNDNPSAVINEA</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab20" orientation="portrait" position="float"><label>Table 20.</label><caption><p>The CD4<sup>+</sup> T cell epitopes of Omp28 by IEDB</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab20.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Percentile rank</th></tr></thead><tbody><tr><td rowspan="10" valign="top" colspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">92&#8211;106</td><td colspan="1" rowspan="1">TITGYSVSTSLTVRV</td><td colspan="1" rowspan="1">0.96</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">90&#8211;104</td><td colspan="1" rowspan="1">EPTITGYSVSTSLTV</td><td colspan="1" rowspan="1">1.20</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">93&#8211;107</td><td colspan="1" rowspan="1">ITGYSVSTSLTVRVR</td><td colspan="1" rowspan="1">1.40</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">91&#8211;105</td><td colspan="1" rowspan="1">PTITGYSVSTSLTVR</td><td colspan="1" rowspan="1">1.70</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">94&#8211;108</td><td colspan="1" rowspan="1">TGYSVSTSLTVRVRE</td><td colspan="1" rowspan="1">1.70</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">95&#8211;109</td><td colspan="1" rowspan="1">GYSVSTSLTVRVREL</td><td colspan="1" rowspan="1">2.10</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">96&#8211;110</td><td colspan="1" rowspan="1">YSVSTSLTVRVRELA</td><td colspan="1" rowspan="1">3.40</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">205&#8211;219</td><td colspan="1" rowspan="1">AAGENSYNVSVNVVF</td><td colspan="1" rowspan="1">7.50</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">207&#8211;221</td><td colspan="1" rowspan="1">GENSYNVSVNVVFEI</td><td colspan="1" rowspan="1">7.80</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">208&#8211;222</td><td colspan="1" rowspan="1">ENSYNVSVNVVFEIK</td><td colspan="1" rowspan="1">9.20</td></tr><tr><td rowspan="10" valign="top" colspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">188&#8211;202</td><td colspan="1" rowspan="1">GQFRTMLAAAPDNSV</td><td colspan="1" rowspan="1">0.75</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">90&#8211;104</td><td colspan="1" rowspan="1">EPTITGYSVSTSLTV</td><td colspan="1" rowspan="1">0.78</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">185&#8211;199</td><td colspan="1" rowspan="1">IARGQFRTMLAAAPD</td><td colspan="1" rowspan="1">0.84</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">92&#8211;106</td><td colspan="1" rowspan="1">TITGYSVSTSLTVRV</td><td colspan="1" rowspan="1">0.89</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">186&#8211;200</td><td colspan="1" rowspan="1">ARGQFRTMLAAAPDN</td><td colspan="1" rowspan="1">0.90</td></tr><tr><td colspan="1" rowspan="1">06</td><td colspan="1" rowspan="1">184&#8211;198</td><td colspan="1" rowspan="1">PIARGQFRTMLAAAP</td><td colspan="1" rowspan="1">0.90</td></tr><tr><td colspan="1" rowspan="1">07</td><td colspan="1" rowspan="1">187&#8211;201</td><td colspan="1" rowspan="1">RGQFRTMLAAAPDNS</td><td colspan="1" rowspan="1">0.90</td></tr><tr><td colspan="1" rowspan="1">08</td><td colspan="1" rowspan="1">91&#8211;105</td><td colspan="1" rowspan="1">PTITGYSVSTSLTVR</td><td colspan="1" rowspan="1">1.10</td></tr><tr><td colspan="1" rowspan="1">09</td><td colspan="1" rowspan="1">93&#8211;107</td><td colspan="1" rowspan="1">ITGYSVSTSLTVRVR</td><td colspan="1" rowspan="1">1.30</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">94&#8211;108</td><td colspan="1" rowspan="1">TGYSVSTSLTVRVRE</td><td colspan="1" rowspan="1">1.60</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab21" orientation="portrait" position="float"><label>Table 21.</label><caption><p>The CD4<sup>+</sup> T cell epitopes of Omp28 by RANKPEP</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab21.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">No.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Score</th></tr></thead><tbody><tr><td rowspan="5" valign="top" colspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">153&#8211;161</td><td colspan="1" rowspan="1">IAKAKTLAD</td><td colspan="1" rowspan="1">16.0</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">82&#8211;90</td><td colspan="1" rowspan="1">PDDKNNLKE</td><td colspan="1" rowspan="1">13.3</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">96&#8211;104</td><td colspan="1" rowspan="1">YSVSTSLTV</td><td colspan="1" rowspan="1">11.5</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">103&#8211;111</td><td colspan="1" rowspan="1">TVRVRELAN</td><td colspan="1" rowspan="1">10.8</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">196&#8211;204</td><td colspan="1" rowspan="1">AAPDNSVPI</td><td colspan="1" rowspan="1">8.5</td></tr><tr><td rowspan="5" valign="top" colspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">01</td><td colspan="1" rowspan="1">151&#8211;159</td><td colspan="1" rowspan="1">NAIAKAKTL</td><td colspan="1" rowspan="1">15.2</td></tr><tr><td colspan="1" rowspan="1">02</td><td colspan="1" rowspan="1">211&#8211;219</td><td colspan="1" rowspan="1">YNVSVNVVF</td><td colspan="1" rowspan="1">10.4</td></tr><tr><td colspan="1" rowspan="1">03</td><td colspan="1" rowspan="1">37&#8211;45</td><td colspan="1" rowspan="1">AKTAREAMT</td><td colspan="1" rowspan="1">8.5</td></tr><tr><td colspan="1" rowspan="1">04</td><td colspan="1" rowspan="1">96&#8211;104</td><td colspan="1" rowspan="1">YSVSTSLTV</td><td colspan="1" rowspan="1">8.1</td></tr><tr><td colspan="1" rowspan="1">05</td><td colspan="1" rowspan="1">44&#8211;52</td><td colspan="1" rowspan="1">MTANNEAMT</td><td colspan="1" rowspan="1">6.1</td></tr></tbody></table></alternatives></table-wrap></p></sec></sec><sec id="sec3-7" sec-type="other"><title>Overlapping epitopes</title><p>These results were compared to find selected sequences with overlapping regions that were identified as dominant B and T epitopes of proteins (<xref rid="tab22 tab23 tab24" ref-type="table">Tables 22&#8211;24</xref>).
<table-wrap id="tab22" orientation="portrait" position="float"><label>Table 22.</label><caption><p>The dominant linear B and T epitopes of Omp22</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab22.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="center" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Immunogenicity</th><th align="center" colspan="1" rowspan="1">Antigenicity</th></tr></thead><tbody><tr><td rowspan="2" valign="top" colspan="1">B epitopes</td><td rowspan="2" valign="top" colspan="1">&#8211;</td><td colspan="1" rowspan="1">120&#8211;138</td><td colspan="1" rowspan="1">AKDNTTSASGWEGGVLIGA</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">164&#8211;174</td><td colspan="1" rowspan="1">SQVNGIEQRNN</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td rowspan="3" valign="top" colspan="1">CD8&#160;+&#160;T epitopes</td><td colspan="1" rowspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">142&#8211;150</td><td colspan="1" rowspan="1">QALSGPLSV</td><td colspan="1" rowspan="1">&#8722;0.2535</td><td colspan="1" rowspan="1">0.3431</td></tr><tr><td rowspan="2" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">41&#8211;49</td><td colspan="1" rowspan="1">PFASRTGAL</td><td colspan="1" rowspan="1">&#8722;0.0439</td><td colspan="1" rowspan="1">&#8722;0.2589</td></tr><tr><td colspan="1" rowspan="1">107&#8211;115</td><td colspan="1" rowspan="1">VYGTAGYGV</td><td colspan="1" rowspan="1">0.1398</td><td colspan="1" rowspan="1">1.4380</td></tr><tr><td rowspan="2" valign="top" colspan="1">CD4&#160;+&#160;T epitopes</td><td colspan="1" rowspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">154&#8211;167</td><td colspan="1" rowspan="1">YDFQRFNDVKSQVN</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">90&#8211;98</td><td colspan="1" rowspan="1">WNGNAKGKV</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab23" orientation="portrait" position="float"><label>Table 23.</label><caption><p>The dominant linear B and T epitopes of Omp19</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab23.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="center" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Immunogenicity</th><th align="center" colspan="1" rowspan="1">Antigenicity</th></tr></thead><tbody><tr><td rowspan="3" valign="top" colspan="1">B epitopes</td><td rowspan="3" valign="top" colspan="1">&#8211;</td><td colspan="1" rowspan="1">24&#8211;47</td><td colspan="1" rowspan="1">VPAGTVQKGNLDSPTQFPNAPSTD</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">109&#8211;130</td><td colspan="1" rowspan="1">ELANLASWAVNGKQLVLYDANG</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">142&#8211;153</td><td colspan="1" rowspan="1">RFDGQTTGGQAV</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td rowspan="4" valign="top" colspan="1">CD8&#160;+&#160;T epitopes</td><td rowspan="3" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">80&#8211;88</td><td colspan="1" rowspan="1">SLGGQSCKI</td><td colspan="1" rowspan="1">&#8722;0.3949</td><td colspan="1" rowspan="1">2.5675</td></tr><tr><td colspan="1" rowspan="1">117&#8211;125</td><td colspan="1" rowspan="1">AVNGKQLVL</td><td colspan="1" rowspan="1">&#8722;0.2722</td><td colspan="1" rowspan="1">0.7816</td></tr><tr><td colspan="1" rowspan="1">146&#8211;154</td><td colspan="1" rowspan="1">GQTTGGQAV</td><td colspan="1" rowspan="1">0.0416</td><td colspan="1" rowspan="1">2.4385</td></tr><tr><td colspan="1" rowspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">136&#8211;144</td><td colspan="1" rowspan="1">LYSSGQGRF</td><td colspan="1" rowspan="1">&#8722;0.2659</td><td colspan="1" rowspan="1">0.2897</td></tr><tr><td rowspan="2" valign="top" colspan="1">CD4&#160;+&#160;T epitopes</td><td colspan="1" rowspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">113&#8211;126</td><td colspan="1" rowspan="1">LASWAVNGKQLVY</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab24" orientation="portrait" position="float"><label>Table 24.</label><caption><p>The dominant linear B and T epitopes of Omp28</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab24.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="center" colspan="1" rowspan="1">Allele</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Sequence</th><th align="center" colspan="1" rowspan="1">Immunogenicity</th><th align="center" colspan="1" rowspan="1">Antigenicity</th></tr></thead><tbody><tr><td rowspan="4" valign="top" colspan="1">B epitopes</td><td rowspan="4" valign="top" colspan="1">&#8211;</td><td colspan="1" rowspan="1">203&#8211;214</td><td colspan="1" rowspan="1">PIAAGENSYNVS</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">41&#8211;60</td><td colspan="1" rowspan="1">REAMTANNEAMTKVLDAMKK</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">1&#8211;12</td><td colspan="1" rowspan="1">QENQMTTQPARI</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">63&#8211;73</td><td colspan="1" rowspan="1">IEDRDLQTGGI</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td rowspan="4" valign="top" colspan="1">CD8&#160;+&#160;T epitopes</td><td rowspan="2" valign="top" colspan="1">HLA-A*02:01</td><td colspan="1" rowspan="1">114&#8211;122</td><td colspan="1" rowspan="1">KILDESVTL</td><td colspan="1" rowspan="1">0.0180</td><td colspan="1" rowspan="1">0.0836</td></tr><tr><td colspan="1" rowspan="1">148&#8211;156</td><td colspan="1" rowspan="1">AVANAIAKA</td><td colspan="1" rowspan="1">0.0765</td><td colspan="1" rowspan="1">0.1095</td></tr><tr><td rowspan="2" valign="top" colspan="1">HLA-A*24:02</td><td colspan="1" rowspan="1">80&#8211;88</td><td colspan="1" rowspan="1">VYPDDKNNL</td><td colspan="1" rowspan="1">&#8722;0.1664</td><td colspan="1" rowspan="1">&#8722;0.3953</td></tr><tr><td colspan="1" rowspan="1">210&#8211;218</td><td colspan="1" rowspan="1">SYNVSVNVV</td><td colspan="1" rowspan="1">&#8722;0.0586</td><td colspan="1" rowspan="1">1.4632</td></tr><tr><td rowspan="2" valign="top" colspan="1">CD4&#160;+&#160;T epitopes</td><td colspan="1" rowspan="1">HLA-DRB*07:01</td><td colspan="1" rowspan="1">96&#8211;111</td><td colspan="1" rowspan="1">YSVSTSLTVRVRELAN</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">HLA-DRB*09:01</td><td colspan="1" rowspan="1">90&#8211;104</td><td colspan="1" rowspan="1">EPTITGYSVSTSLTV</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr></tbody></table></alternatives></table-wrap></p></sec><sec id="sec3-8" sec-type="other"><title>Class I immunogenicity and antigenic prediction</title><p>The immunogenicity and antigenicity analysis of CD8<sup>+</sup> T cell dominant epitopes were performed by the MHC I immunogenicity prediction tool of the IEDB server and VaxiJen 2.0 server, respectively. Both immunogenicity and antigenicity were positive for epitope, which could be further analysed. The results are shown in <xref rid="tab22 tab23 tab24" ref-type="table">Tables 22&#8211;24</xref>.</p></sec><sec id="sec3-9" sec-type="other"><title>Design of the multi-epitope vaccine construct</title><p>To construct the final chimaeric subunit vaccine sequence, the predicted epitope of B cells was used as a template and compared with the T cell epitope. Epitopes whose sequences overlap with the B cell epitope were preferentially chosen for the final vaccine construct (<xref rid="tab25 tab26 tab27" ref-type="table">Tables 25&#8211;27</xref>). Finally, six sequences were selected as constructs, including sequences 120&#8211;138, 154&#8211;174 of Omp22, and epitope sequences 24&#8211;47, 109&#8211;130, 142&#8211;153 of Omp19 and sequence 41&#8211;73 of Omp28. These epitopes were connected by amino acid linkers. HEYGAEALERAG and GGGS linkers bind the T-epitopes and the B-epitopes, while the carrier sequences connect the N-terminal and C-terminal via the EAAAK linker (<xref rid="tab28" ref-type="table">Table 28</xref>).
<table-wrap id="tab25" orientation="portrait" position="float"><label>Table 25.</label><caption><p>Comparative analysis of all predicted B cell, HLA-I and HLA-II epitopes of Omp22</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab25.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">S. no</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Final B Epitope<break/>&#65288;Omp22&#65289;</th><th align="center" colspan="1" rowspan="1">HLA-II</th><th align="center" colspan="1" rowspan="1">HLA-I</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">120&#8211;138</td><td colspan="1" rowspan="1">AKDNTTSASGWEGGVLIGA</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">164&#8211;174</td><td colspan="1" rowspan="1">SQVNGIEQRNN</td><td colspan="1" rowspan="1">YDFQRFNDVKSQVN</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">107&#8211;115</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">VYGTAGYGV</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">90&#8211;98</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">WNGNAKGKV</td><td colspan="1" rowspan="1">&#8211;</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab26" orientation="portrait" position="float"><label>Table 26.</label><caption><p>Comparative analysis of all predicted B cell, HLA-I and HLA-II epitopes of Omp19</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab26.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">S. no.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Final B epitope<break/>&#65288;Omp19&#65289;</th><th align="center" colspan="1" rowspan="1">HLA-II</th><th align="center" colspan="1" rowspan="1">HLA-I</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">24&#8211;47</td><td colspan="1" rowspan="1">VPAGTVQKGNLDSPTQFPNAPSTD</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">109&#8211;130</td><td colspan="1" rowspan="1">ELANLASWAVNGKQLVLYDANG</td><td colspan="1" rowspan="1">LASWAVNGKQLVY</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">142&#8211;153</td><td colspan="1" rowspan="1">RFDGQTTGGQAV</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">GQTTGGQAV</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab27" orientation="portrait" position="float"><label>Table 27.</label><caption><p>Comparative analysis of all predicted B cell, HLA-I and HLA-II epitopes of Omp28</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab27.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="&#x2013;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">S. no.</th><th align="center" colspan="1" rowspan="1">Position</th><th align="center" colspan="1" rowspan="1">Final B epitope<break/>&#65288;Omp28&#65289;</th><th align="center" colspan="1" rowspan="1">HLA-II</th><th align="center" colspan="1" rowspan="1">HLA-I</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">203&#8211;214</td><td colspan="1" rowspan="1">PIAAGENSYNVS</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">41&#8211;73</td><td colspan="1" rowspan="1">REAMTANNEAMTKVLDAMKKAGIEDRDLQTGGI</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">1&#8211;12</td><td colspan="1" rowspan="1">QENQMTTQPARI</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">96&#8211;111</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">YSVSTSLTVRVRELAN</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">90&#8211;104</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">EPTITGYSVSTSLTV</td><td colspan="1" rowspan="1">&#8211;</td></tr></tbody></table></alternatives></table-wrap>
<table-wrap id="tab28" orientation="portrait" position="float"><label>Table 28.</label><caption><p>Predict allergenicity, antigenicity and solubility of vaccine structure</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_tab28.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Epitope sequence position with carrier</th><th align="center" colspan="1" rowspan="1">The complete sequence of Vaccine construct</th><th align="center" colspan="1" rowspan="1">Allergenicity (threshold 35%)</th><th align="center" colspan="1" rowspan="1">Antigenicity (threshold 0.5)</th><th align="center" colspan="1" rowspan="1">Solubility (threshold 0.5)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Omp22(120&#8211;138, 154&#8211;174) and Omp19 (24&#8211;47, 109&#8211;130, 142&#8211;153) and Omp28 (41&#8211;73) epitope with carrier sequence</td><td colspan="1" rowspan="1"><bold>EAAAK</bold>MAENPNIDDLPAPLLAALGAADLALATVNDLIANLRERAEETRAETRTRVEERRARLTKFQEDLPEQFIELRDKFTTEELRKAAEGYLEAATNRYNELVERGEAALQRLRSQTAFEDASARAEGYVDQAVELTQEALGTVASQTRAVGERAAKLVGIEL<bold>EAAAKAKFVAAWTLKAAAGGGS</bold>AKDNTTSASGWEGGVLIGA<bold>GGGS</bold>YDFQRFNDVKSQVNGIEQRNN<bold>GGGSAKFVAAWTLKAAAGGGS</bold>VPAGTVQKGNLDSPTQFPNAPSTD<bold>HEYGAEALERAG</bold>ELANLASWAVNGKQLVLYDANG<bold>HEYGAEALERAG</bold>RFDGQTTGGQAV<bold>HEYGAEALERAG</bold>REAMTANNEAMTKVLDAMKKAGIEDRDLQTGGI<bold>HEYGAEALERAGAKFVAAWTLKAAAGGGS</bold></td><td colspan="1" rowspan="1">7.37&#8211;11.30</td><td colspan="1" rowspan="1">0.788</td><td colspan="1" rowspan="1">0.866</td></tr></tbody></table></alternatives></table-wrap></p></sec><sec id="sec3-10" sec-type="other"><title>Allergenicity, antigenicity and solubility evaluation</title><p>The online software SDAP was employed to predict the allergenicity of the vaccine construct. The similarity (%) between the sequence of the construct and the most similar template was between 7.37 and 11.30, which was lower than the threshold of 35%, so the vaccine construct was considered non-allergenic. The antigenicity of this vaccine sequence was analysed using VaxiJen 2.0 service software. The antigen value of 0.788 was predicted, which was higher than the threshold value of 0.5, so the vaccine construct was considered to have good antigenicity. The vaccine construct was soluble with SOLpro SVM value 0.866, which was considered to have good solubility (<xref rid="tab28" ref-type="table">Table 28</xref>).</p></sec><sec id="sec3-11" sec-type="other"><title>Prediction of the secondary structure of the vaccine construct</title><p>Using SOPMA server to analyse the secondary structure of the vaccine. The results have shown that the structure had 67.32% <italic toggle="yes">alpha-helix</italic>, 3.39% <italic toggle="yes">extended strand</italic>, 7.62% <italic toggle="yes">Beta turn</italic> and 21.13% <italic toggle="yes">random coil</italic> (<xref ref-type="fig" rid="fig06">Fig. 6</xref>).
<fig id="fig06" fig-type="fig" orientation="portrait" position="float"><label>Fig. 6.</label><caption><p>Analysis of the secondary structure of the vaccine construct by SOMPA. The sequence length of the vaccine construct is 407 amino acids. The blue h is <italic toggle="yes">Alpha helix</italic> and accounts for 67.32%, the red e is <italic toggle="yes">extended strand</italic> and accounts for 7.62%, the yellow c is <italic toggle="yes">random coil</italic> and accounts for 21.13%, the green t is <italic toggle="yes">Beta turn</italic> and accounts for 3.93%.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_fig6.jpg"/></fig></p></sec><sec id="sec3-12" sec-type="other"><title>Physicochemical analysis of the vaccine construct</title><p>The vaccine construct was made up of 407 amino acids and had a molecular weight of approximately 43&#160;kDa. The molecular formula was C<sub>1855</sub>H<sub>2947</sub>N<sub>551</sub>O<sub>612</sub>S<sub>4</sub>. The theoretical pI value was 4.95 and contained 45 strongly alkaline (&#160;+&#160;) amino acids (K, R) and 61 strongly acidic (&#8211;) amino acids (D, E). The instability index was 29.87 (the instability index of the stable protein &lt;40), which was predicted to be a stable protein. The grand average of hydropathicity (GRAVY): &#8722;0.439 (GRAVY ranges from &#8722;2 to 2, negative values indicate hydrophilic proteins) and were classified as a hydrophilic construct. The results show that the vaccine construct has good characteristics of initiating an immunogenic response.</p></sec><sec id="sec3-13" sec-type="other"><title>Prediction and verification of the 3D structure of the vaccine construct</title><p>The results showed that the C-score of the three-dimensional (3D) model was shown as &#8722;1.52, and the TM score and RMSD of the model were 0.53&#160;&#177;&#160;0.15 and 10.4&#160;&#177;&#160;4.6&#160;&#197;, respectively (<xref ref-type="fig" rid="fig07">Fig. 7a</xref>). The structure validation was achieved by Ramachandran graph analysis. The results showed that there were 86.4%, 9.6% and 4.0% residues in favourable, allowable and outlier regions, respectively (<xref ref-type="fig" rid="fig07">Fig. 7b</xref>).
<fig id="fig07" fig-type="fig" orientation="portrait" position="float"><label>Fig. 7.</label><caption><p>The 3D structure prediction and validation of the vaccine construct. (a) The 3D structure of model construct. (b) Ramachandran diagram of the mock vaccine, showing 96.0 residues in the allowable range. Ramachandran plot takes the angles of <italic toggle="yes">Phi</italic> and <italic toggle="yes">Pis</italic> as the abscissa and ordinate. <italic toggle="yes">Phi</italic> is the rotation angle of C&#8722;N bond on the left side of <italic toggle="yes">&#945;</italic> carbon in a peptide unit, and <italic toggle="yes">Pis</italic> is the rotation angle of C&#8722;C bond on the right side of <italic toggle="yes">&#945;</italic> carbon. The area inside the yellow coil is completely allowed, the area inside the blue coil is allowed and the area outside the blue coil is not allowed. When the scatter in the blue coil and the yellow coil exceeds 90%, the tertiary structure of the model conforms to rules of stereochemistry.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0950268821001229_fig7.jpg"/></fig></p></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>Brucellosis is a serious infectious disease with low cure rate and complex clinical symptoms. At present, vaccine is considered to be the most effective measure to prevent Brucellosis [<xref rid="ref32" ref-type="bibr">32</xref>]. In this study, we used bioinformatics methods to design a multi-epitope vaccine construct, which provided detailed insights into the initial stages of vaccine development.</p><p>Based on previous studies, the Omp22, Omp19 and Omp28 were evaluated as having good immunogenicity and inducing immune protection <italic toggle="yes">in vivo.</italic> Moreover, Omp22 and Omp28 were highly conservative, stable and not easily degraded, which provides favourable conditions for later vaccine construction. Therefore, it is of great significance to select the Omp22, Omp19 and Omp28 as candidate proteins for constructing a multi-epitope vaccine against <italic toggle="yes">Brucella</italic>. As far as we know, there is no multi-epitope vaccine design based on these three candidate proteins.</p><p>SignalP-5.0 server was employed for predicting the signal peptide of the Omp22, Omp19 and Omp28. We respectively removed the signal peptide sequences of Omp22, Omp19 and Omp28, namely 1&#8211;24 aa (MFKRSITAAALGAAVMAFAGSAFA), 1&#8211;19 aa (MGISKASLLSLAAAGIVLA) and 1&#8211;28 aa (MNTRASNFLAASFSTIMLVGAFSLPAFA). Signal peptides were usually located at the start of the protein translation region, affecting protein expression. To predict T/B epitopes more accurately, it was necessary to remove the signal peptide. It was found that the highly hydrophilic region of the antigen was conducive to the interaction with the antibody binding sites, and the more accessible residues on the surface of the antigen, the more conducive to the binding of the antibody [<xref rid="ref33" ref-type="bibr">33</xref>]. Therefore, we screened out highly hydrophobic and inaccessible regions of these outer membrane proteins to ensure that the epitopes were located on the more hydrophilic and accessible residues (<xref ref-type="fig" rid="fig01">Figs 1</xref> and <xref ref-type="fig" rid="fig02">2</xref>).</p><p>The key to preparing an epitope vaccine is to obtain the epitopes of relative antigen [<xref rid="ref34" ref-type="bibr">34</xref>]. Therefore, in this study, the T cell and B cell epitopes of three candidate proteins were screened by the variety of epitope prediction software, which improved the accuracy of epitope prediction [<xref rid="ref35" ref-type="bibr">35</xref>], then dominant epitopes with both T and B cell were elected. The immune response of <italic toggle="yes">Brucella</italic> mainly depends on active T cells. However, many vaccines can only induce B cell immunity [<xref rid="ref36" ref-type="bibr">36</xref>]. CD8<sup>+</sup> T cells can effectively lyse and kill infected cells, thus exposing <italic toggle="yes">Brucella</italic> to the outside of cells and triggering other germicidal mechanisms. Therefore, we analysed the antigenicity and immunogenicity of CD8<sup>+</sup> T cell epitopes to ensure that the epitope vaccine can effectively activate CD8<sup>+</sup> T cells. Considering that CD4 <sup>+</sup> T cells are needed to induce appropriate antibody immune response, we also included CD4 <sup>+</sup> T cell epitopes in the vaccine construct. Our multi-epitope vaccine was designed based on T/B cell epitopes, it is possible to selectively activate specific B cells, CTL and T helper cells to achieve a fully protected and sustained immune response. Finally, six dominant epitopes were identified by a series of comparisons. There were two dominant epitopes (120&#8211;138, 154&#8211;174) from the Omp22, three dominant epitopes (24&#8211;47, 109&#8211;130, 142&#8211;153) from the Omp19 and one dominant epitope (41&#8211;73) from the Omp28.</p><p>As shown in <xref rid="tab28" ref-type="table">Table 28</xref>, our vaccine construct is composed of HBHA&#65292;PADRE (as a carrier) located at the N- and C-terminal end of the vaccine sequence&#65292;six sets of T/ B cell epitopes in the middle of the vaccine construct, which were connected to each other by appropriate linkers. Using GSSS and HEYGAEALERAG cleavable linkers to separate these three domains from each other to enhance the expression of epitopes. These linkers have two key roles in the structure of epitope vaccines: firstly, to prevent the generation of binding epitopes (new epitopes) for the designed epitope vaccine; secondly, to promote immune processing and presentation of HLA-II binding epitopes [<xref rid="ref37" ref-type="bibr">37</xref>]. Besides, for linker sequences, we usually use glycine (G) and serine (S) as component amino acids of linker sequences [<xref rid="ref38" ref-type="bibr">38</xref>]. Because glycine (G) and serine (S) are the smallest of all amino acids and the most flexible&#65292;have no chiral carbon and can be placed between epitope sequences without affecting the conformation and function of either sides. Moreover, due to the functional characteristics of HBHA, the EAAAK linker was used to connect HBHA to the N terminal of vaccine construct as a carrier to ensure the interaction between HBHA and other vaccine fragments was minimised and provides better separation [<xref rid="ref39" ref-type="bibr">39</xref>]. PADRE sequence has been reported to reduce the effect of human HLA-DR polymorphism and can enhance the long-term immune response by inducing CD4<sup>+</sup> T cells [<xref rid="ref40" ref-type="bibr">40</xref>]. Therefore, we added the PADRE sequence to the vaccine construct.</p><p>Finally, we constructed a multi-epitope vaccine with a length of 407 amino acids. The physicochemical, structural and immunological properties of the vaccine construct were predicted by various bioinformatics methods. It is necessary to examine any possible allergenicity at the early stage of vaccine design [<xref rid="ref41" ref-type="bibr">41</xref>]. Our vaccine construct was shown to be non-allergenic on SDAP software, making it more effective as a candidate vaccine. The multi-epitope vaccine construct showed higher scores of antigenicity on the VaxiJen 2.0 server. The vaccine construct showed the solubility of more than 0.5 (0.886), which exhibited that the vaccine construct will be highly soluble during its heterologous expression in <italic toggle="yes">E. coli</italic>. The solubility of recombinant protein in <italic toggle="yes">E. coli</italic> is the key to many biochemical and functional studies. In short, the vaccine construct is soluble, non-allergic and antigenic peptides.</p><p>The molecular weight (MW) of the final protein is estimated to be 43&#160;kDa. The estimated theoretical pI was 4.95, indicating that the vaccine construct was acidic. The predicted value of the instability index was 29.87, which indicated that the protein was very stable after expression, thus further confirmed its possibility. The predicted score of the GRAVY was &#8722;0.439&#65292;which shows that the protein would be a hydrophilic construct. The results show that the vaccine construct has good characteristics of initiating an immunogenic response. Analyses of the secondary structure showed that the protein mainly contained 67.32% <italic toggle="yes">alpha helices</italic>, with 7.62% <italic toggle="yes">extended strand</italic>, and they have been identified as important &#8216;structural antigens&#8217; types. The 3D structure of the vaccine construct was modelled by I-TASSER. RMSD and TM scores are index to evaluate the reliability and accuracy of the prediction model. A TM-score more than 0.5 always shows the correct topology model, and C-score was used to show its confidence. Expected TM score of 0.53&#160;&#177;&#160;0.15 validated the accuracy of the model. The chimaeric structure displayed appropriate characteristics based on the Ramachandran plot's results. Ramachandran plot analysis indicates that 96% of the residues are initiated in the favoured and allowed regions, with fewer (4%) residues in the outlier region. This indicated that the quality of the whole model is acceptable. In this study, a multi-epitope vaccine construct was designed against brucellosis by immunodominant epitopes from antigens of <italic toggle="yes">Brucella</italic>, including Omp22, Omp19 and Omp28 using the combination of online bioinformatics servers. However, there is a lack of confirmation of the protective efficacy of the vaccine construct in animal models. More studies with both in vivo and in vitro methods would be designed in the future to assess the potency of the vaccine construct.</p><p>In conclusion, this study uses a large number of immunoinformatic approaches to find the vaccine construct to fight against <italic toggle="yes">Brucella</italic> infection, which provides a theoretical basis for future laboratory experiments.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors are thankful to the State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases, The First Affiliated Hospital of Xinjiang Medical University, PR China.</p></ack><notes id="nts1" notes-type="other"><title>Authors' contributions</title><p>This study was conceived and designed by Jianbing Ding and Fengbo Zhang. Bioinformatic analysis was performed by Zhiqiang Chen and Tong Sha. The manuscript was drafted by Zhiqiang Chen and Fengbo Zhang and edited by Jianbing Ding. Ethics approval and consent to participate.</p></notes><notes id="nts2" notes-type="other"><title>Financial support</title><p>This study was supported by grants (No. 81860352, No. 81860375, No.81560322) from the National Natural Science Foundation of China and funds for the Xinjiang Key construction Project of the 13th Five-Year Plan (basic medicine).</p></notes><sec id="nts3" sec-type="COI-statement"><title>Conflict of interest</title><p>The authors declared no potential conflicts of interest.</p></sec><notes id="nts4" notes-type="other"><title>Ethical standards</title><p>This article does not contain any studies using human participants or animals.</p></notes><sec id="sec-das1" sec-type="data-availability"><title>Data availability statement</title><p>The authors confirm that the data supporting the findings of this study are available within the article and its references.</p></sec><ref-list id="reflist1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal" id="cite1"><string-name name-style="western"><surname>Corbel</surname><given-names>MJ</given-names></string-name> (<year>1997</year>) <article-title>Brucellosis: an overview</article-title>. <source>Emerging Infectious Diseases</source><volume>3</volume>, <fpage>213</fpage>&#8211;<lpage>221</lpage>.<pub-id pub-id-type="pmid">9204307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid0302.970219</pub-id><pub-id pub-id-type="pmcid">PMC2627605</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal" id="cite2"><string-name name-style="western"><surname>Eisenberg</surname><given-names>T</given-names></string-name><etal/> (<year>2020</year>) <article-title>Expanding the host range: infection of a reptilian host (<italic toggle="yes">Furcifer pardalis</italic>) by an atypical <italic toggle="yes">Brucella</italic> strain</article-title>. <source>Antonie van Leeuwenhoek</source><volume>113</volume>, <fpage>1531</fpage>&#8211;<lpage>1537</lpage>.<pub-id pub-id-type="pmid">32699967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10482-020-01448-9</pub-id><pub-id pub-id-type="pmcid">PMC7481142</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal" id="cite3"><string-name name-style="western"><surname>Waldrop</surname><given-names>SG</given-names></string-name> and <string-name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></string-name> (<year>2019</year>) <article-title>Intracellular invasion and survival of <italic toggle="yes">Brucella neotomae</italic>, another possible zoonotic <italic toggle="yes">Brucella</italic> species</article-title>. <source>PLoS One</source><volume>14</volume>, <fpage>e0213601</fpage>.<pub-id pub-id-type="pmid">30943213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0213601</pub-id><pub-id pub-id-type="pmcid">PMC6447175</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal" id="cite4"><string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name><etal/> (<year>2011</year>) <article-title>Rapid multiplex PCR assay for the simultaneous detection of the <italic toggle="yes">Brucella</italic> genus, <italic toggle="yes">B. abortus</italic>, <italic toggle="yes">B. melitensis</italic>, and <italic toggle="yes">B. suis</italic></article-title>. <source>Journal of Microbiology and Biotechnology</source><volume>21</volume>, <fpage>89</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">21301197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4014/jmb.1007.07051</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal" id="cite5"><string-name name-style="western"><surname>Jia</surname><given-names>B</given-names></string-name><etal/> (<year>2017</year>) <article-title><italic toggle="yes">Brucella endocarditis</italic>: clinical features and treatment outcomes of 10 cases from Xinjiang, China</article-title>. <source>Journal of Infection</source><volume>74</volume>, <fpage>512</fpage>&#8211;<lpage>514</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jinf.2017.01.011</pub-id><pub-id pub-id-type="pmid">28143754</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal" id="cite6"><string-name name-style="western"><surname>Aslam</surname><given-names>M</given-names></string-name><etal/> (<year>2020</year>) <article-title>Potential druggable proteins and chimeric vaccine construct prioritization against <italic toggle="yes">Brucella melitensis</italic> from species core genome data</article-title>. <source>Genomics</source><volume>112</volume>, <fpage>1734</fpage>&#8211;<lpage>1745</lpage>.<pub-id pub-id-type="pmid">31678593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygeno.2019.10.009</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal" id="cite7"><string-name name-style="western"><surname>Zhang</surname><given-names>FB</given-names></string-name><etal/> (<year>2019</year>) <article-title>The immunogenicity of OMP31 peptides and its protection against <italic toggle="yes">Brucella melitensis</italic> infection in mice</article-title>. <source>Scientific Reports</source><volume>9</volume>, <fpage>3512</fpage>.<pub-id pub-id-type="pmid">30837598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-40084-w</pub-id><pub-id pub-id-type="pmcid">PMC6401381</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal" id="cite8"><string-name name-style="western"><surname>Masjedian Jezi</surname><given-names>F</given-names></string-name><etal/> (<year>2019</year>) <article-title>Immunogenic and protective antigens of <italic toggle="yes">Brucella</italic> as vaccine candidates</article-title>. <source>Comparative Immunology, Microbiology and Infectious Diseases</source><volume>65</volume>, <fpage>29</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cimid.2019.03.015</pub-id><pub-id pub-id-type="pmid">31300122</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal" id="cite9"><string-name name-style="western"><surname>Shojaei</surname><given-names>M</given-names></string-name><etal/> (<year>2018</year>) <article-title>Immunogenicity evaluation of plasmids encoding <italic toggle="yes">Brucella melitensis</italic> Omp25 and Omp31 antigens in BALB/c mice</article-title>. <source>Iranian Journal of Basic Medical Sciences</source><volume>21</volume>, <fpage>957</fpage>&#8211;<lpage>964</lpage>.<pub-id pub-id-type="pmid">30524697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22038/IJBMS.2018.27540.6722</pub-id><pub-id pub-id-type="pmcid">PMC6272067</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal" id="cite10"><string-name name-style="western"><surname>Sha</surname><given-names>T</given-names></string-name><etal/> (<year>2020</year>) <article-title>Bioinformatics analysis of candidate proteins Omp2b, P39 and BLS for <italic toggle="yes">Brucella</italic> multivalent epitope vaccines</article-title>. <source>Microbial Pathogenesis</source><volume>147</volume>, <fpage>104318</fpage>.<pub-id pub-id-type="pmid">32531499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micpath.2020.104318</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal" id="cite11"><string-name name-style="western"><surname>Li</surname><given-names>ZW</given-names></string-name><etal/> (<year>2019</year>) <article-title>Immunoinformatics prediction of OMP2b and BCSP31 for designing multi-epitope vaccine against <italic toggle="yes">Brucella</italic></article-title>. <source>Molecular Immunology</source><volume>114</volume>, <fpage>651</fpage>&#8211;<lpage>660</lpage>.<pub-id pub-id-type="pmid">31557626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2019.09.013</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal" id="cite12"><string-name name-style="western"><surname>Vishnu</surname><given-names>US</given-names></string-name><etal/> (<year>2015</year>) <article-title>Novel vaccine candidates against <italic toggle="yes">Brucella melitensis</italic> identified through reverse vaccinology approach</article-title>. <source>Omics: A Journal of Integrative Biology</source><volume>19</volume>, <fpage>722</fpage>&#8211;<lpage>729</lpage>.<pub-id pub-id-type="pmid">26479901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/omi.2015.0105</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal" id="cite13"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name><etal/> (<year>2012</year>) <article-title>Vaccination with recombinant flagellar proteins FlgJ and FliN induce protection against <italic toggle="yes">Brucella abortus</italic> 544 infection in BALB/c mice</article-title>. <source>Veterinary Microbiology</source><volume>161</volume>, <fpage>137</fpage>&#8211;<lpage>144</lpage>.<pub-id pub-id-type="pmid">22854331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2012.07.016</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal" id="cite14"><string-name name-style="western"><surname>Coloma-Rivero</surname><given-names>RF</given-names></string-name><etal/> (<year>2020</year>) <article-title>The role of the flagellar protein FlgJ in the virulence of <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Frontiers in Cellular and Infection Microbiology</source><volume>10</volume>, <fpage>178</fpage>.<pub-id pub-id-type="pmid">32411617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2020.00178</pub-id><pub-id pub-id-type="pmcid">PMC7198779</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal" id="cite15"><string-name name-style="western"><surname>Terwagne</surname><given-names>M</given-names></string-name><etal/> (<year>2013</year>) <article-title>Innate immune recognition of flagellin limits systemic persistence of <italic toggle="yes">Brucella</italic></article-title>. <source>Cellular Microbiology</source><volume>15</volume>, <fpage>942</fpage>&#8211;<lpage>960</lpage>.<pub-id pub-id-type="pmid">23227931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cmi.12088</pub-id><pub-id pub-id-type="pmcid">PMC4026035</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal" id="cite16"><string-name name-style="western"><surname>Du</surname><given-names>ZQ</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name> and <string-name name-style="western"><surname>Wang</surname><given-names>JY</given-names></string-name> (<year>2016</year>) <article-title>Immunogenicity analysis of a novel subunit vaccine candidate molecule-recombinant L7/L12 ribosomal protein of <italic toggle="yes">Brucella suis</italic></article-title>. <source>Applied Biochemistry and Biotechnology</source><volume>179</volume>, <fpage>1445</fpage>&#8211;<lpage>1455</lpage>.<pub-id pub-id-type="pmid">27075455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12010-016-2076-x</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal" id="cite17"><string-name name-style="western"><surname>Pratt</surname><given-names>AJ</given-names></string-name><etal/> (<year>2015</year>) <article-title>Structural, functional, and immunogenic insights on Cu,Zn superoxide dismutase pathogenic virulence factors from <italic toggle="yes">Neisseria meningitidis</italic> and <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Journal of Bacteriology</source><volume>197</volume>, <fpage>3834</fpage>&#8211;<lpage>3847</lpage>.<pub-id pub-id-type="pmid">26459556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JB.00343-15</pub-id><pub-id pub-id-type="pmcid">PMC4652047</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal" id="cite18"><string-name name-style="western"><surname>Martin-Martin</surname><given-names>AI</given-names></string-name><etal/> (<year>2008</year>) <article-title>Importance of the Omp25/Omp31 family in the internalization and intracellular replication of virulent <italic toggle="yes">B. ovis</italic> in murine macrophages and HeLa cells</article-title>. <source>Microbes &amp; Infection</source><volume>10</volume>, <fpage>706</fpage>&#8211;<lpage>710</lpage>.<pub-id pub-id-type="pmid">18457973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2008.02.013</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal" id="cite19"><string-name name-style="western"><surname>Tibor</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Decelle</surname><given-names>B</given-names></string-name> and <string-name name-style="western"><surname>Letesson</surname><given-names>JJ</given-names></string-name> (<year>1999</year>) <article-title>Outer membrane proteins Omp10, Omp16, and Omp19 of <italic toggle="yes">Brucella</italic> spp. are lipoproteins</article-title>. <source>Infection &amp; Immunity</source><volume>67</volume>, <fpage>4960</fpage>&#8211;<lpage>4962</lpage>.<pub-id pub-id-type="pmid">10456959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.67.9.4960-4962.1999</pub-id><pub-id pub-id-type="pmcid">PMC96837</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal" id="cite20"><string-name name-style="western"><surname>Kaushik</surname><given-names>P</given-names></string-name><etal/> (<year>2010</year>) <article-title>Protection of mice against <italic toggle="yes">Brucella abortus</italic> 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides</article-title>. <source>Veterinary Research Communications</source><volume>34</volume>, <fpage>119</fpage>&#8211;<lpage>132</lpage>.<pub-id pub-id-type="pmid">20013309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11259-009-9337-x</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal" id="cite21"><string-name name-style="western"><surname>Golshani</surname><given-names>M</given-names></string-name><etal/> (<year>2018</year>) <article-title>Comparison of the protective immunity elicited by a <italic toggle="yes">Brucella</italic> cocktail protein vaccine (rL7/L12 + rTOmp31 + rSOmp2b) in two different adjuvant formulations in BALB/c mice</article-title>. <source>Molecular Immunology</source><volume>103</volume>, <fpage>306</fpage>&#8211;<lpage>311</lpage>.<pub-id pub-id-type="pmid">30343119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2018.10.002</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal" id="cite22"><string-name name-style="western"><surname>Armenteros</surname><given-names>JJA</given-names></string-name><etal/> (<year>2019</year>) <article-title>SignalP 5.0 improves signal peptide predictions using deep neural networks</article-title>. <source>Nature Biotechnology</source><volume>37</volume>, <fpage>420</fpage>&#8211;<lpage>423</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41587-019-0036-z</pub-id><pub-id pub-id-type="pmid">30778233</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal" id="cite23"><string-name name-style="western"><surname>Wilkins</surname><given-names>MR</given-names></string-name><etal/> (<year>1999</year>) <article-title>Protein identification and analysis tools in the ExPASy server</article-title>. <source>Methods in Molecular Biology</source><volume>112</volume>, <fpage>531</fpage>&#8211;<lpage>552</lpage>.<pub-id pub-id-type="pmid">10027275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1385/1-59259-584-7:531</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal" id="cite24"><string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name><etal/> (<year>2012</year>) <article-title>UCSF Chimera, MODELLER, and IMP: an integrated modeling system</article-title>. <source>Journal of Structural Biology</source><volume>179</volume>, <fpage>269</fpage>&#8211;<lpage>278</lpage>.<pub-id pub-id-type="pmid">21963794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsb.2011.09.006</pub-id><pub-id pub-id-type="pmcid">PMC3410985</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal" id="cite25"><string-name name-style="western"><surname>Yang</surname><given-names>JY</given-names></string-name><etal/> (<year>2015</year>) <article-title>The I-TASSER suite: protein structure and function prediction</article-title>. <source>Nature Methods</source><volume>12</volume>, <fpage>7</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25549265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.3213</pub-id><pub-id pub-id-type="pmcid">PMC4428668</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal" id="cite26"><string-name name-style="western"><surname>Doytchinova</surname><given-names>IA</given-names></string-name> and <string-name name-style="western"><surname>Flower</surname><given-names>DR</given-names></string-name> (<year>2007</year>) <article-title>VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines</article-title>. <source>BMC Bioinformatics</source><volume>8</volume>, <fpage>4</fpage>.<pub-id pub-id-type="pmid">17207271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-8-4</pub-id><pub-id pub-id-type="pmcid">PMC1780059</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal" id="cite27"><string-name name-style="western"><surname>Rana</surname><given-names>A</given-names></string-name> and <string-name name-style="western"><surname>Akhter</surname><given-names>Y</given-names></string-name> (<year>2016</year>) <article-title>A multi-subunit based, thermodynamically stable model vaccine using combined immunoinformatics and protein structure based approach</article-title>. <source>Immunobiology</source><volume>221</volume>, <fpage>544</fpage>&#8211;<lpage>557</lpage>.<pub-id pub-id-type="pmid">26707618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imbio.2015.12.004</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal" id="cite28"><string-name name-style="western"><surname>Ghaffari-Nazari</surname><given-names>H</given-names></string-name><etal/> (<year>2015</year>) <article-title>Improving multi-epitope long peptide vaccine potency by using a strategy that enhances CD4 + T help in BALB/c mice</article-title>. <source>PLoS One</source><volume>10</volume>, <fpage>e0142563</fpage>.<pub-id pub-id-type="pmid">26556756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0142563</pub-id><pub-id pub-id-type="pmcid">PMC4640540</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal" id="cite29"><string-name name-style="western"><surname>Ivanciuc</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Schein</surname><given-names>CH</given-names></string-name> and <string-name name-style="western"><surname>Braun</surname><given-names>W</given-names></string-name> (<year>2003</year>) <article-title>SDAP: database and computational tools for allergenic proteins</article-title>. <source>Nucleic Acids Research</source><volume>31</volume>, <fpage>359</fpage>&#8211;<lpage>362</lpage>.<pub-id pub-id-type="pmid">12520022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkg010</pub-id><pub-id pub-id-type="pmcid">PMC165457</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal" id="cite30"><string-name name-style="western"><surname>Magnan</surname><given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Randall</surname><given-names>A</given-names></string-name> and <string-name name-style="western"><surname>Baldi</surname><given-names>P</given-names></string-name> (<year>2009</year>) <article-title>SOLpro: accurate sequence-based prediction of protein solubility</article-title>. <source>Bioinformatics (Oxford, England)</source><volume>25</volume>, <fpage>2200</fpage>&#8211;<lpage>2207</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btp386</pub-id><pub-id pub-id-type="pmid">19549632</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal" id="cite31"><string-name name-style="western"><surname>Deleage</surname><given-names>G</given-names></string-name> (<year>2017</year>) <article-title>ALIGNSEC: viewing protein secondary structure predictions within large multiple sequence alignments</article-title>. <source>Bioinformatics (Oxford, England)</source><volume>33</volume>, <fpage>3991</fpage>&#8211;<lpage>3992</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btx521</pub-id><pub-id pub-id-type="pmid">28961944</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal" id="cite32"><string-name name-style="western"><surname>Hou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name> and <string-name name-style="western"><surname>Peng</surname><given-names>Q</given-names></string-name> (<year>2019</year>) <article-title>The advances in brucellosis vaccines</article-title>. <source>Vaccine</source><volume>37</volume>, <fpage>3981</fpage>&#8211;<lpage>3988</lpage>.<pub-id pub-id-type="pmid">31176541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.05.084</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal" id="cite33"><string-name name-style="western"><surname>Pourseif</surname><given-names>MM</given-names></string-name><etal/> (<year>2018</year>) <article-title>A novel B- and helper T-cell epitopes-based prophylactic vaccine against <italic toggle="yes">Echinococcus granulosus</italic></article-title>. <source>BioImpacts: BI</source><volume>8</volume>, <fpage>39</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">29713601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15171/bi.2018.06</pub-id><pub-id pub-id-type="pmcid">PMC5915707</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal" id="cite34"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name><etal/> (<year>2013</year>) <article-title>Bioinformatic prediction of epitopes in the Emy162 antigen of <italic toggle="yes">Echinococcus multilocularis</italic></article-title>. <source>Experimental &amp; Therapeutic Medicine</source><volume>6</volume>, <fpage>335</fpage>&#8211;<lpage>340</lpage>.<pub-id pub-id-type="pmid">24137185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2013.1142</pub-id><pub-id pub-id-type="pmcid">PMC3786825</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal" id="cite35"><string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name><etal/> (<year>2014</year>) <article-title>Prokaryotic expression and identification of B- and T-cell combined epitopes of Em95 antigen of <italic toggle="yes">Echinococcus multilocularis</italic></article-title>. <source>International Journal of Clinical &amp; Experimental Pathology</source><volume>7</volume>, <fpage>5117</fpage>&#8211;<lpage>5122</lpage>.<pub-id pub-id-type="pmid">25197385</pub-id><pub-id pub-id-type="pmcid">PMC4152075</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal" id="cite36"><string-name name-style="western"><surname>Verma</surname><given-names>S</given-names></string-name><etal/> (<year>2018</year>) <article-title>Multi-epitope DnaK peptide vaccine against <italic toggle="yes">S. typhi</italic>: an in silico approach</article-title>. <source>Vaccine</source><volume>36</volume>, <fpage>4014</fpage>&#8211;<lpage>4022</lpage>.<pub-id pub-id-type="pmid">29861180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.05.106</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal" id="cite37"><string-name name-style="western"><surname>Nezafat</surname><given-names>N</given-names></string-name><etal/> (<year>2016</year>) <article-title>Designing an efficient multi-epitope peptide vaccine against <italic toggle="yes">Vibrio cholerae</italic> via combined immunoinformatics and protein interaction based approaches</article-title>. <source>Computational Biology &amp; Chemistry</source><volume>62</volume>, <fpage>82</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">27107181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiolchem.2016.04.006</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal" id="cite38"><string-name name-style="western"><surname>van Rosmalen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Krom</surname><given-names>M</given-names></string-name> and <string-name name-style="western"><surname>Merkx</surname><given-names>M</given-names></string-name> (<year>2017</year>) <article-title>Tuning the flexibility of glycine-serine linkers to allow rational design of multidomain proteins</article-title>. <source>Biochemistry</source><volume>56</volume>, <fpage>6565</fpage>&#8211;<lpage>6574</lpage>.<pub-id pub-id-type="pmid">29168376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biochem.7b00902</pub-id><pub-id pub-id-type="pmcid">PMC6150656</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal" id="cite39"><string-name name-style="western"><surname>Arai</surname><given-names>R</given-names></string-name><etal/> (<year>2001</year>) <article-title>Design of the linkers which effectively separate domains of a bifunctional fusion protein</article-title>. <source>Protein Engineering</source><volume>14</volume>, <fpage>529</fpage>&#8211;<lpage>532</lpage>.<pub-id pub-id-type="pmid">11579220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/protein/14.8.529</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal" id="cite40"><string-name name-style="western"><surname>Solanki</surname><given-names>V</given-names></string-name> and <string-name name-style="western"><surname>Tiwari</surname><given-names>V</given-names></string-name> (<year>2018</year>) <article-title>Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against <italic toggle="yes">Acinetobacter baumannii</italic></article-title>. <source>Scientific Reports</source><volume>8</volume>, <fpage>9044</fpage>.<pub-id pub-id-type="pmid">29899345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-26689-7</pub-id><pub-id pub-id-type="pmcid">PMC5997985</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal" id="cite41"><string-name name-style="western"><surname>Validi</surname><given-names>M</given-names></string-name>, <etal/> (<year>2018</year>) <article-title>Immuno-informatics based approaches to design a novel multi epitope-based vaccine for immune response reinforcement against Leptospirosis</article-title>. <source>Molecular Immunology</source><volume>104</volume>, <fpage>128</fpage>&#8211;<lpage>138</lpage>.<pub-id pub-id-type="pmid">30448609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2018.11.005</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>